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 Burkitt Lymphoma (BL) is a B cell non-Hodgkin lymphoma that occurs as three distinct 
subtypes, namely: endemic, sporadic, and immunodeficiency/HIV-associated. This cancer 
represents a frequent cause of mortality among HIV+ people in Southern Africa which has the 
highest incidence of HIV/AIDS worldwide. Recent reports associate a direct oncogenic 
function of HIV in BL development. However, the molecular mechanisms underlying this 
HIV-associated malignancy are not well understood. This study explores the oncogenic 
potential of HIV-1 protein Tat in BL via its ability to manipulate the expression of c-MYC and 
activation-induced cytidine deaminase (AID), two key drivers of BL progression.  
 
Using dual-luciferase reporter assays, HIV-1 Tat was shown to enhance the activity of the c-
MYC promoter (-2324 bp - +537 bp), which corresponded with elevated c-MYC protein levels 
in BL cells (Ramos) expressing HIV-1 Tat.  By generating sequential promoter deletions, the 
minimal promoter region mediating HIV-1 Tat induced activation was identified.  Site-directed 
mutagenesis indicated that this response was mediated by AP-1 binding elements, and co-
immunoprecipitation assays revealed that HIV-1 Tat and the AP-1 factor JunB interacted 
within the same complex. Chromatin immunoprecipitation assays confirmed that JunB bound 
the c-MYC promoter in vivo under the influence of HIV-1 Tat.  
 
The effect of HIV-1 Tat on the expression of the DNA editing enzyme AID was also 
investigated. Dual-luciferase assays revealed that HIV-1 Tat could enhance the activity of the 
three regulatory regions of the AICDA gene, namely R1, R2 and R4. This translated into 
xix 
 
elevated AID protein expression in Ramos cells expressing HIV-1 Tat, which was also 
reflected in an increase in genomic instability as shown by enhanced phosphorylated H2AX 
expression. Sequential promoter deletions of the R1 promoter did not lead to a loss in HIV-1 
Tat-mediated activation, pointing to potential post-transcriptional regulation. Indeed, HIV-1 
Tat was found to downregulate the expression of hsa-miRNA-181b-5p, a known repressor of 
the murine Aicda gene. Furthermore, using reporter assays, we show that an hsa-miRNA-181b-
5p mimic could repress AICDA via the full-length 3’UTR which contains three putative binding 
elements for the miRNA.  
 
To date, this study reveals that HIV-1 Tat induced c-MYC promoter activation is mediated by 
two AP-1 binding sites. HIV-1 Tat was shown to couple with JunB and bind to both AP-1 sites 
on the c-MYC promoter inducing promoter activation. Furthermore, this study reveals a novel 
mechanism of AID deregulation via HIV-1 Tat-mediated miRNA perturbation. Lastly, we 
show that HIV-1 Tat interferes with hsa-miRNA-181b-5p expression in B cells, alleviating 



























This literature review provides a broad introduction to Human Immunodeficiency Virus (HIV) 
associated Non-Hodgkin Lymphoma (NHL) and gives detailed descriptions about the 
molecular features behind Burkitt Lymphoma (BL), a common HIV associated malignancy. It 
describes the recent advances in the field, specifically, the novel findings elucidating the 
mutagenic landscape of the two most common HIV-associated NHLs, namely Diffuse Large 
B-Cell Lymphoma (DLBCL) and BL. It describes the role of c-MYC chromosomal 
rearrangements and mutations in carcinogenesis and highlights the involvement of the DNA 
modifying enzyme Activation-Induced cytidine Deaminase (AID) in generating these genetic 
lesions. It also provides an overview of the known oncogenic roles of HIV and its viral proteins 
in both lymphoid and non-lymphoid cancers highlighting the gaps in knowledge of the 
molecular mechanisms behind HIV-associated Burkitt Lymphoma (HIV-BL) development. 
Parts of Section 1.3 of this literature review have been published as a review article in the 
Journal of Cancer Research and Clinical Oncology (Rios, L.A.d., Cloete, B. & Mowla, S. 
Activation-induced cytidine deaminase: in sickness and in health. J Cancer Res Clin 




Infection caused by the Human Immunodeficiency Virus (HIV) and the development of 
Acquired Immunodeficiency Syndrome (AIDS) remains a global health care problem with an 
estimated 38 million people living with HIV/AIDS in 2019 1. Although new infections per year 
have decreased worldwide, from the 1996 high of 3.4 million to 1.7 million estimated for 2019, 
efforts are still required to meet the 2020 UNAIDS goal of reducing this number to 0.5 million.  
According to UNAIDS, Eastern and Southern Africa are the regions with the highest burden 
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of HIV, with 20.7 million people living with HIV/AIDS, followed by Asia and the Pacific with 
5.8 million 1. South Africa is the country with the largest HIV positive population in the world 
with 13% of the population infected with the virus (7.8 million) as reported in 2020 2. Though 
access to antiretroviral therapy has improved significantly in South Africa since the start of the 
public sector Highly Active Antiretroviral Therapy (HAART) programme in 2004, many still 
do not receive treatment - almost 30% of HIV positive individuals are currently still not 
accessing treatment 1.  
 
The introduction of HAART in South Africa, beginning in the early 2000s, has significantly 
improved the life expectancy of people living with HIV (PLWH), however, this has led to a 
dramatic increase in the incidence of HIV-associated co-morbidities including HIV-associated 
NHL 3,4. While HAART allows for the reconstitution of the immune system, it does not 
eliminate the virus and latent reservoirs of the virus remain 5–7. These, as well as other 
concomitant and chronic infections, are responsible for B-cell hyperactivation, leading to the 
transformation of these cells 8,9.  
 
HIV positive individuals are at a 60-200-fold greater risk of developing NHLs compared to the 
general population 10,11.  Two main B-cell derived NHLs are associated with HIV infection, 
namely DLBCL and BL and notably, the prevalent subtype of DLBCL which occurs in PLWH 
is Activated B-Cell like DLBCL (ABC-DLBCL), which is highly aggressive and less 
responsive to current treatment regimens 12. Another aggressive subset of DLBCLs known as 
Plasmablastic Lymphoma (PBL) is also highly prevalent in HIV positive individuals 13. 
Interestingly this subset shares similar molecular characteristics with BL which are discussed 
later in this chapter (Section 1.3.1). The introduction of HAART combined with 
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chemotherapeutic treatment (combination therapy) has resulted in an improved survival 
outcome 14. However, the prognosis of HIV-associated NHL remains poor with a 2-year  
overall survival (OS) rate of 55.6% (48.5 to 63.8) reported for HIV-associated DLBCL and 
53.1% (40.2 to 70.1) for HIV-associated BL15–17. Therefore,   there is an urgent need to further 
define the molecular pathology of HIV-DLBCL and HIV-BL to develop better treatment 
approaches. Several studies found the incidence of HIV-BL to still be relatively high post the 
HAART era with some reporting no improvement at all 16,18,19. It is well known that infection 
with the Epstein-Barr Virus (EBV) is associated with the development of a specific subtype of 
BL 20. However, this is observed to a lesser extent in HIV-associated BL indicating that HIV 
may play a more direct role in lymphomagenesis.  
 
 Intriguingly, BL seems to develop in HIV positive patients with a relatively high CD4 
lymphocyte count 21. This indicates that the immunocompromised status of these HIV positive 
individuals is not the only factor predisposing them to develop BL. Therefore, a better 
understanding of the role of HIV in the development of BL, and the molecular mechanisms 
behind this interaction is required for the improved treatment strategies of HIV-BL patients. 
This project is aimed at defining the relationship between HIV infection and BL, with a focus 
on specific host lymphoma driver genes, and therefore the sections below elaborate on the 
molecular pathology of this cancer.  
 
1.3 Burkitt Lymphoma  
 
Burkitt Lymphoma is an aggressive Non-Hodgkin lymphoma of germinal or post-germinal 
centre B cell origin. In 1958,  Denis Burkitt was the first physician to report that children with 
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jaw tumours in Uganda had similar tumours at multiple additional sites, particularly in the 
abdomen 22. The cancer was initially described as a sarcoma by Burkitt; however, it was later 
reclassified as a lymphoma. BL occurs in three main forms: endemic BL (eBL), sporadic BL 
(sBL) and HIV-associated BL (HIV-BL). The eBL form occurs predominantly along the 
malaria belt including equatorial Africa, Papua New Guinea and Northern Brazil. It is the most 
prevalent cancer among children in these regions, and presents with a swollen jaw and/or 
abdomen due to the formation of large tumours 23,24.  Notably, eBL is highly associated with 
Epstein Barr Virus (EBV) infection (detected in >90% of cases), with the virus being first 
described in eBL derived cells by  Epstein et al in 1964 25–28. The sBL subtype occurs outside 
of the malaria belt, and it is less frequent but presents a similar morphology to the endemic 
form, although it is not as highly associated with EBV infection (20% of cases) 24,27. A recent 
genome-wide sequencing study by Grande et al (2019) revealed that EBV status has a 
significant impact on the genetic landscape of paediatric BL, potentially superseding clinical 
variant status. Here it was shown that both EBV positive eBL and sBL had elevated levels of 
AICDA expression, correlating with a higher somatic hypermutation burden compared to EBV 
negative cases albeit with lower rates observed in coding regions. 29. Of interest to this research 
project is HIV-BL which has lower associations with EBV (30-40% of cases) and malaria 
infection as compared to eBL 21,27. The molecular characteristics and pathobiology of this 
subtype remain undefined and form the basis of this project.  
 
BL is highly aggressive, characterised by its rapid tumour growth, with a doubling rate of 24-
48 hours and under the microscope, the characteristic appearance of a BL tumour section upon 
Haematoxylin and Eosin (H&E) staining is the presence of a "starry sky" pattern, imparted by 
scattered macrophages phagocytizing cell debris and apoptotic cells (Figure 1.1). A hallmark 
of BL is the translocation and overexpression of oncogenic c-MYC which is detected through 
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Fluorescent In-Situ Hybridization (FISH). Although treatment regimens vary according to 
geographical setting, a common treatment approach for BL utilizes CHOP 
(Cyclophosphamide, Hydroxydaunorubicin (also called doxorubicin or adriamycin) Oncovin 
(vincristine) and Prednisone) or R(rituximab)-CHOP chemotherapy as well as a surgical 
intervention if necessary 21,30–32. In the case of HIV-BL, the introduction of HAART before or 
during chemotherapeutic intervention has been shown to improve survival as compared to 
chemotherapy only regimens 33,34. 
 
Figure 1.1: H&E stain of a BL tumour biopsy. Staining with Haematoxylin and Eosin results 
in a starry sky appearance with macrophages (denoted by black arrows) containing apoptotic 






1.3.1 Molecular hallmarks of BL 
 
The pathogenesis of BL is strongly related to the overexpression of c-MYC, a Basic-Helix-
Loop-Helix-Leucine Zipper transcription factor, which is an important regulator of apoptosis, 
cell growth and cellular metabolism 35. c-MYC acts broadly in the regulation of mammalian 
gene expression forming part of the Extended MYC Network 36. The c-MYC protein forms 
heterodimers with either MAX or MLX to bind to E-box elements (5’-CACGTG-3’) thereby 
promoting gene transcription 37–39. Under normal conditions, c-MYC expression is governed by 
mitogenic signals which activate transcription factors responsible for c-MYC 
promoter/enhancer activation. Importantly, c-MYC can immortalize cells and is one of the 
most overexpressed proteins in cancer and is, therefore, involved in the carcinogenesis of many 
human cancers 34. Approximately 28% of the data sets from The Cancer Genome Atlas 
(TCGA), which includes 33 tumour types, harbour c-MYC genetic alterations 40. These 
mutations are often non-coding, preserving c-MYC’s potent pro-transcriptional ability but 
abrogate the regulatory mechanisms that govern its activity. The involvement of c-MYC in 
lymphoma has been well described. Importantly, in the context of BL, the translocation of the 
c-MYC gene is a hallmark of the disease. This translocation results in the overexpression of c-
MYC allowing for the aggressive growth of the mutant cells 41. Three main translocations are 
known to occur, the most frequent (70-80% of patients) being t(8;14)(q24;q32), involving the 
juxtaposition of c-MYC in chromosome band 8q24 to the immunoglobulin heavy chain gene 
(IGH) in chromosome band 14q32. The other two are t(2;8)(p12;q24), which involves the IG 
kappa-light chain locus in the 2p12, and can be detected in 15% of BL patients; and 
t(8;22)(q24;q11), involving the IG lambda-light chain genes in the 22q11, and is detected in 
5% of BL patients 21. Although the translocated c-MYC gene is the main contributor to the c-
MYC overexpression in BL, c-MYC can still be expressed from its loci on chromosome 8 
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although at a much lower rate42. Furthermore, mutations that affect c-MYC activity and 
stability have been reported in both BL and DLBCL 43. 
 
Recently, next-generation sequencing of sporadic BL has shown frequent genetic alterations to 
many genes further exemplifying the molecular complexity and heterogeneity of BL. Notably, 
TCF3 (E2A) and its repressor ID3 which are both involved in the differentiation of B cells and 
cell cycle progression, often carry mutations in BL 44,45. A whole-genome sequencing study 
analysing BL tumour samples compared to matched germline controls revealed recurring 
mutations in the ID3 gene in 34% of samples. These mutations were shown to increase cell 
cycle progression from G1 to S phase in vitro 46. Alterations to these genes have also been 
reported in HIV-associated BL with at least 67% of cases presenting with ID3 and/or TCF3 
mutations 47,48. An important feature of this malignancy is its dependency on the germinal 
centre (GC) dark zone (DZ) cell survival programme, relying on BCL6, FOXO1, MYB and 
TCF3 expression, and the PTEN-PI3K-AKT pathway which is maintained at similar levels to 
normal DZ B cells 49–51.  
 
The main driver of the c-MYC translocation has been identified as the DNA deaminating 
enzyme AID 52.  AID is a DNA modifying enzyme which plays an essential role in humoral 
immunity. Under normal conditions, the expression of AID is largely restricted to activated B 
cells and ensures that a diverse array of antibodies can be produced. However, when 
deregulated it can lead to genetic lesions including translocations 52–55. The normal function of 




1.4 The DNA modifying enzyme AID  
 
The Human body is constantly challenged by a myriad of antigens and therefore requires a 
highly efficient way of protecting itself from these assaults. There are three lines of defence 
that aid in preventing pathogenic disease, namely, physical barriers, non-specific innate 
immunity, and specific adaptive immunity. Of the three lines of defence of the immune system, 
adaptive immunity is the most complex and sophisticated, being able to rapidly adapt to meet 
new challenges. Adaptive immunity is mediated through B and T lymphocytes working 
together to recognise foreign antigens and generate specific antibodies able to eliminate these 
antigens. The first line of diversification of antibodies occurs during B cell maturation when 
V(D)J recombination takes place 56. After naïve B cells encounter antigens in secondary 
lymphoid tissues two additional processes occur namely somatic hypermutation (SHM) and 
class switch recombination (CSR). The AID enzyme plays a central role in these diversification 
mechanisms 53 
 
1.4.1 Somatic Hypermutation and Class Switch Recombination 
 
Mutations are introduced into the variable region of the Immunoglobulin (Ig) gene at a rate of 
up to 10-3–10-4 mutations per base/division, which is much higher when compared to the 
background 10-9 rate of mutation per base/division within the rest of the genome 57.  AID targets 
the “hot spot motif”  RGYW/WRCY with R= A/G, Y= C/T and W=A/T at a higher frequency 
compared to the rest of the genome 58. During SHM, AID converts deoxycytosine (dC) in the 
variable region to deoxyuridine (dU) mutations occur when replication proceeds before the 
correction of the mismatch or through the mismatch repair (MMR) and base excision repair 




Figure 1.2: The role of AID in somatic hypermutation. In the variable region of Ig loci AID 
causes a change from cytidine to uracil. Mutations can occur if replication is carried out before 
DNA repair or through aberrant BER or MMR DNA repair mechanisms. The resulting mutated 
sections of DNA allow for the diversification of the hypervariable region of antibodies (image 
adapted from https://www.anaptysbio.com/technology/.). 
 
Effector function of antibodies is changed through CSR, a process that occurs between two 
switch regions (S) found upstream of each constant heavy chain (CH) gene and results in the 
switching of antibody isotype expression from the initially expressed IgM to IgD, IgG, IgA, 
and IgE isotypes. AID converts dC to dU and these are removed by the actions of Uracil-DNA 
Glycosylase (UNG) and apyrimidinic endonuclease (APE1) leaving ssDNA breaks, dsDNA 
breaks are formed when ssDNA breaks are close to each other on opposite DNA strands or by 
MMR repair pathway. The intervening DNA is excised as a switch circle, resulting in the 
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variable region being juxtaposed to the downstream CH gene, these are then joined by either 





Figure 1.3: CSR mediated via the AID enzyme. CSR is a gene rearrangement process that 
allows for the change of expressed Ig constant regions (C) resulting in the change from IgM to 
IgG, IgA, IgE or IgD isotypes. AID deaminates dCs at S regions (S) causing DSBs. The 
intermediate DNA is excised as a switch circle and the DSB are joined through either NHEJ or 







1.4.2 AID leads to DNA demethylation 
 
More recently, AID has become recognised as a DNA demethylator, linked to its ability to 
deaminate cytidine 63. The conversion of deoxycytosine (dC) to deoxyuridine (dU) can lead to 
the disruption of CpG methylation sites in DNA, thus altering gene expression. This role for 
AID has only recently been recognised, with studies showing both genome-wide and gene-
specific demethylation 64. Although further investigations are needed, there is sufficient data 
to support the notion that AID can alter gene expression in B cell malignancy through active 
DNA demethylation 64–66. 
 
1.4.3 The physiological regulation of AID 
 
Due to its DNA mutagenic function, the expression of AID is strictly regulated within normal 
B cells and occurs at the transcription, post-transcription, and post-translation levels, involving 
nuclear/cytoplasmic distribution and stability, as well as enzymatic function. A comprehensive 
summary of these regulatory mechanisms is displayed in Figure 1.4 67,68.  Four conserved 
regulatory regions have been described for the human AICDA gene containing a variety of 
transcription factor binding sites (TFBS) including Sp1, Sp3, HoxC4-OCT, STAT 6 and others. 
Region 4 is primarily responsible for AICDA expression upon stimulation of B cells while 
region 1 seems to be responsible for basal expression.  
 
Regulation of AID also occurs post-transcriptionally with the repressive action of miRNAs. To 
date, four miRNAs have been implicated in the repression of  AID expression namely: miR-
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155, miR-93, miR-29b and miR181b 69–72.  However, most of the research has focused on 
murine Aicda and there is limited research done on the repression of human AICDA by miRNA. 
 
Post-translational regulation of AID is mediated by proteins like the Protein Kinase A (PKA) 
73, with phosphorylation of S38, T140, T27 and S3 being important for AID function during 
SHM and CSR 74–77. AID is predominantly localised to the cytoplasm of B cells where its 
stabilization is dependent on Heat shock protein 90 (Hsp90) coupling 78. However, AID acts 
on ssDNA and is therefore shuttled into and out of the nucleus through its nuclear localization 
signal (NLS) and nuclear export signal (NES) located in the N and C termini respectively 79. 
Furthermore, AID activity is limited by the cell cycle, in the early G1 phase when chromatin 
de-condense and transcription reinitiates, ssDNA is exposed allowing AID access to its 
preferred substrate 80. Off-target AID activity is then limited when the nuclear envelope 
reforms and AID molecules are shuttled out of the nucleus by a Chromosome Maintenance 1 
(CRM-1) dependant mechanism or rapidly degraded in the nucleus via a ubiquitin- and ATP- 
independent proteasomal degradation pathway mediated by REGgamma (REG-γ) or through 
ubiquitination by Cullin 7 E3 ubiquitin ligase 80–83 Together, these levels of regulation ensure 









Figure 1.4: Summary of the AICDA/AID regulatory mechanisms. AID activity is regulated 
at multiple levels. Transcriptional regulation is mediated via four conserved regions which 
contain multiple TFBS. Posttranscriptional AID is regulated by several miRNAs. Binding 
partners like HSP90, promote AID stability in the cytoplasm. Posttranslational mechanism of 
regulation includes phosphorylation of the AID protein at select amino acids which govern its 
ability to induce SHM or CSR. Degradation of AID occurs by polyubiquitination, preventing 




1.4.4 The role of AID in lymphoid cancers  
 
The involvement of AID in lymphoid malignancies has been well described, with aberrant 
expression described in both B and T cell-derived lymphomas 67,84–90. The main translocation 
event, t(8;14) in human BL and t(12;15) in murine plasmacytomas involving the c-MYC and 
IgH loci is driven by AID 52,54,86,91. Importantly, Ramiro et al (2004) showed that AID 
expression was essential for the c-MYC/IgH translocation event in Balb/c-IL6tg transgenic 
mice, with AID-/- mice failing to develop the characteristic translocation events in B cells 52. 
Duquette et al (2005) showed, using electron microscopy, that AID binds G-loops that form 
during transcription of the c-MYC gene as well as the immunoglobulin S region. These G-loop 
regions were mapped to the breakpoints related to c-MYC translocation 92.  
 
Besides its link to MYC translocation, AID mutational activity has also been reported in other 
important B cell-specific genes like the ID3 gene resulting in its inactivation 93. A recent whole-
genome sequencing study by Panea et al (2019) elucidated new driver mutations in BL 
including IGLL5, BACH2, BTG2, BCL6, BCL7A, TCL1A, IRF8, CXCR4, ZFP36L1, and S1PR2 
which all harboured somatic hypermutation signatures in promoter regions 94. 
 
Further association between AID and the development of BL relates to its relationship with the 
human gammaherpesvirus Epstein-Barr virus (EBV), a virus that is closely associated with 
eBL.  Studies suggest that EBV directly targets AID 95,96 and that this is reliant on the latency 
program of EBV infection that differs according to the lymphoproliferative malignancy 97. 
Recent studies have shed light on the mechanisms whereby EBV proteins including the Latent 
Membrane Protein 1 (LMP1), Epstein-Barr nuclear antigen A2 (EBNA2) and Epstein-Barr 
virus nuclear antigen 3C (EBNA3C) induce AID expression 29,98–102. These studies highlight 
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the complex relationship between EBV factors and AID expression and support a collaborative 
role between EBV and AID in lymphomagenesis.  
 
Although AID is an essential enzyme of the adaptive immune system which, under normal 
conditions, enables antibody affinity and specificity diversification. It is also associated with a 
range of pathological conditions (Figure 1.5 & 1.6). Under these pathophysiological 
conditions including infection with EBV, malaria and HIV, AID can become deregulated, 
leading to off-target mutational and epigenetic changes to DNA, affecting the expression and 
activity of both tumour promoters and tumour suppressors. This has been described for both 









Figure 1.5: AID activity in physiological vs pathophysiological settings. A) normal 
physiological AID function, which occurs in activated B cells in germinal centres, where AID 
acts on the Ig locus, inducing SHM and CRS. B) aberrant activity under a pathological setting 
where off-target AID activity occurs at non-Ig genes leading to carcinogenesis (image adapted 









Figure 1.6: Illustration of AID deregulation, affected downstream genes and cellular 
consequences in lymphoid and non-lymphoid cancers. A) AID deregulation by pathogenic 
agents leads to off-target mutations in key oncogenes/ tumour suppressors inhibiting apoptosis 
and promoting proliferation, culminating in mature B cell lymphomas. B) AID dysregulation 
by UV irradiation, pathogenic infection and chronic inflammation leads to off-target mutations 
in genes involved in EMT and proliferation, ultimately leading to the development of 







1.5 The role of HIV in carcinogenesis 
 
1.5.1 HIV and cancer  
 
As discussed earlier, people infected with HIV are predisposed to develop certain types of 
cancer both AIDS-defining, such as Kaposi Sarcoma (KS), NHL, and cervical cancer and non-
AIDS-defining cancers including Hodgkin lymphoma, head and neck cancer, anal cancer, and 
lung cancer 3,104. Although the introduction of HAART has decreased the incidence of AIDS-
defining cancers, NHLs continue to present as a common cause of mortality in PLWH, 
especially in the Southern African context15,105. The most commonly occurring NHL in HIV 
positive individuals is BL followed closely by DLBCL and PBL (Figure 1.7). While previously 
this association was seen to be exclusively due to the immunodeficiency caused by HIV, recent 
evidence points to HIV playing a more direct and active role in cellular transformation and 







Figure 1.7: Graphs showing the distribution of HIV associated lymphomas from two 
independent studies conducted in the Western Cape, South Africa. A) Distribution of HIV 
associated lymphomas at the Tygerberg Hospital from 2002-2009 106. B) Retrospective analysis 
showing the distribution of HIV-associated lymphomas from Groote Schuur Hospital from 





1.5.2 Oncogenic role of HIV proteins  
 
HIV proteins are essential for the survival and propagation of the virus. However, some of 
these viral proteins like HIV-1 Nef and Tat have also been recently implicated in 
carcinogenesis, which has been well described in the context of KS development. Importantly, 
HIV-1 proteins are actively secreted into the serum of infected individuals and are detectable 
even in patients undergoing HAART, who are virally suppressed 108–110. HIV-1 Nef is one of 
the first transcribed proteins to accumulate in the early stages of macrophage infection 111. 
Upon entering the cell it is thought to interfere with host gene expression, promoting the 
development of HIV related cancers 112. A study by Xue et al (2014) showed that Nef and the 
HHV8 protein K1 could synergistically promote cellular proliferation and angiogenesis (two 
important processes in oncogenesis) through the PTEN/AKT/mTOR pathway mediated by the 
miRNA-718 in both primary Human Vascular Endothelial Cells (HUVECs) and EA.hy926 
cells.113. Similarly, another study by Yao et al (2015) also utilizing the same cell lines showed 
that ectopic or soluble HIV-1 Tat and K1 could synergistically increase miRNA-891a-5p 
expression leading to elevated NFκB expression resulting in increased angiogenesis and 
cellular proliferation 114. HIV-1 Tat can also accelerate KS tumorigenesis induced by another 
HHV8 protein, Kaposin A. Both these proteins activate multiple signalling pathways such as 
the MEK/ERK and PI3K/Akt pathways which together result in increased proliferation of  
NIH3T3 mouse fibroblast cells in vitro and increased tumour formation in vivo in both nude 
and immunocompetent mice 115. 
 
A limited number of studies have reported on the oncogenic potential of HIV proteins in NHL. 
For instance, the HIV protein p17 has been shown to promote the DNA binding activity of c-
MYC and CREB, both important regulators in cell proliferation, differentiation, and survival. 
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p17 increases the phosphorylation of these factors through time and dose-dependent activation 
of the cAMP/PKA and MEK/ERK signalling pathways. This deregulation is specifically 
important in the context of B cell lymphomas because c-MYC and CREB are both transcription 
factors involved in the pathogenesis of these diseases 116. A study by Giagulli et al (2011) also 
showed that p17 variants differentially regulate PTEN expression with one variant (p17Δ36) 
leading to the repression of PTEN and the subsequent promotion of B cell proliferation 117. 
HIV proteins can also mimic important growth factors inducing tumorigenic processes like 
angiogenesis. HIV-1 Tat can recognise and bind to vascular endothelial growth factor receptor 
(VEGFR) acting as a mimic of the VEGF protein, leading to the increased density of micro-
vessels in BL associated tumours 118.  Furthermore, HIV-1 Tat has also been reported to induce 
epigenetic modifications in HIV related B cell lymphomas, with evidence showing that HIV-1 
Tat leads to DNMT1 and DNMT3a/b overexpression by the repression of the miRNA148-152 
cluster which are known regulators of DNMTs. This aberrant expression of DNMTs thus leads 
to hypermethylation of the INK4/p16 gene promoting the oncogenic phenotype by alleviating 
cell cycle inhibition 119. Recently, our research group has shown that BL cells exposed to 
recombinant HIV-1 Nef have increased transcription of both c-MYC and AICDA 120. This was 
correlated with increased AID activity, demonstrated by exacerbated  DNA damage within 
these cells. Taken together these studies highlight the importance of HIV-1 proteins as host 
genome regulators in the development of cancer. 
 
1.5.3 Oncogenic role of HIV- 1 Tat 
 
This project is focused on the role of HIV-1 Tat in oncogenesis, its normal function and 
interaction with the cellular host genome are discussed here.  HIV-1 Tat is a small protein (86-
101 amino acids) (Figure 1.8) that has a crucial role in HIV DNA transcription and survival. 
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HIV-1 Tat is a highly versatile protein with many functions attributed to its basic domain, an 
essential structural component for its interactions with both viral and host factors 121. Viral 
HIV-1 Tat activity requires the transactivation-responsive region (TAR) 122, a stem-loop 
structure present at the 5’ end of all HIV mRNAs. The TAR region is recognised by the basic 
arginine-rich domain 123,124. HIV-1 Tat increases the rate of gene transcription, central to this 
role is HIV-1 Tat’s ability to bind to P-TEFb which is then recruited to RNA Polymerase II, 
releasing stalled mRNA synthesis 125–127. HIV-1 Tat also recruits other host TFs to the LTR 
region of the integrated viral genome promoting the initiation of mRNA synthesis 128–130. 
However, HIV-1 Tat does not only target the viral DNA/mRNA motifs; it has also been shown 
to bind to the host genome with many reports indicating that it influences host gene expression.  
 
 
Figure 1.8: Structure of HIV-1 Tat protein showing the specific amino acid-rich domains. 
HIV-1 Tat is a small protein of approximately 14 kDa. It is composed of five distinct amino 
acid domains: a proline-rich domain (Pro), cysteine-rich domain (Cys), core region, basic 
domain (basic), a glutamine-rich domain (Gln) and an RDG motif. Numbers annotated 
represent amino acid positions. 
 
A human genome-wide study by Marban et al (2011)  revealed that HIV-1 Tat binds to a variety 
of regions within the genome, notably they showed that there was significant binding occurring 
within repetitive DNA elements, with the majority being Alu elements, which are the most 
common transposable elements in the human genome 131,132. They also reported that in Jurkat 
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cells (acute T cell leukaemia cell line), 7% of HIV-1 Tat-bound regions are near transcription 
start sites (TSS) within gene promoters. They also showed that HIV-1 Tat binding within the 
human genome coincided with genes involved in T cell biology and immune response. A 
subsequent study to the work done by Marban et al (2011), using an improved methodology, 
further demonstrated HIV-1 Tat’s preference for the promoter and 5’-UTR regions of genes 
(24% enrichment) and, importantly, it was also shown that these associations were conserved 
at the gene expression level, which was assessed through RNA-Seq 133. Another human 
genome-wide study conducted by Dhamija et al (2015)  showed that the HIV-1 Tat protein acts 
as a repressor of the c-Rel gene by interacting with specific NFkB sites on the c-Rel promoter, 
which they proposed aids in the persistent viral infection of the T cells 134. There is also 
evidence that HIV-1 Tat indirectly influences the transcription of certain genes. Lim & 
Garzino-Demo, (2000) demonstrated that HIV-1 Tat increased binding activity of transcription 
factors SP1, AP-1 and NFkB to their DNA elements on the Monocyte Chemoattractant Protein 
1 (MCP-1) promoter resulting in increased MCP-1 expression in astrocytes. HIV-1 Tat has also 
been shown to deregulate pRb2/p130 mRNA expression and inactivates its ability to arrest cell 
proliferation by binding to its pocket region, positively affecting the growth of HIV-associated 
NHL tumours 136,137. Overall, these studies showed that the extent of HIV-1 Tat binding to the 
human genome was greater than previously thought and that the regulatory role of HIV-1 Tat 
is not only observed in the viral genome but also in the host genome. 
 
As previously discussed, HIV proteins including HIV-1 Tat promote KS development and 
aggressiveness in HIV positive patients 113. Zhou et al (2013) showed that HIV-1 Tat promotes 
vIL-6 induction of factors involved in angiogenesis and tumorigenesis (VEGF, b-FGF, CD31 
and cyclin D1) through the regulation of the PI3K/PTEN/AKT/GSK-3b Pathway 138. 
Importantly Germini et al (2017) recently showed that exposing healthy B cells to HIV-1 Tat 
25 
 
promotes the co-localization of the c-MYC locus to that of the IgH locus 139. In a more recent 
publication, the same group demonstrated that HIV-1 Tat induces AICDA gene expression in 
healthy peripheral blood B cells resulting in DNA damage located at both the c-MYC and IgH 
loci 140. Taken together, these studies indicate that HIV-1 Tat and AID can work synergistically 
to promote c-MYC translocation and overexpression.  
HIV-1 Tat has been shown to alter cellular gene expression through altering cellular miRNA 
expression 114,141. This was recently shown in Kaposi sarcoma, where HIV-1 Tat was shown to 
act synergistically with Orf-K1, a KSHV protein, to promote the expression of miRNA-891a-
5p. The authors showed that this cooperation led to the promotion of angiogenesis through the 
NFkB pathway 114. Work focusing on HIV Associated Neurocognitive Disorder (HAND) has 
also shown that HIV-1 Tat can bind to multiple miRNAs preventing them from accessing and 
repressing the translation of target mRNAs. Importantly, one of the miRNAs which were 
identified in the study was miRNA-181-b, a known regulator of AID 141,142. The role of HIV-
proteins in the deregulation of miRNAs involved in B-cell biology has not yet been elucidated, 
therefore, research in this area is needed to further explore the molecular pathology of HIV-
NHLs. 
 
1.6 Aims of this study 
 
 
HIV-1 associated NHLs remain a clinical challenge in the South African context. To develop 
better treatment strategies a more in-depth knowledge of the molecular pathobiology of these 
malignancies is required. Previous preliminary work in our group had investigated the effect 
of HIV-1 Tat on key lymphoma driver genes and found that it could enhance the transcription 
of both c-MYC and AICDA. This study aimed to (i) confirm this preliminary finding through a 
more comprehensive investigation, and (ii) define the mechanisms via which HIV-Tat 
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enhanced the expression of these genes. The results of the investigations on the c-MYC 
oncogene are presented in Chapter 2, and that of AICDA/AID is presented in Chapter 3. In 
Chapter 4, the overall findings of the study are discussed and placed within the context of our 








































Chapter 2:  Investigating the mechanisms 











2.1 Introduction  
 
The main function of the HIV-1 Tat protein is to stimulate and enhance transcription of the 
integrated HIV-1 genome, thus,  the protein is essential for the virus’s survival and propagation. 
Key to this role is HIV- 1 Tat’s ability to bind to the transcription elongation factor P-TEFb 
which is then recruited to RNA Polymerase II releasing stalled mRNA synthesis 125–127. HIV-
1 Tat also recruits other host transcription factors (TFs) to the LTR region of the integrated 
viral genome which promotes initiation of mRNA synthesis 128–130. Importantly, HIV-1 Tat is 
actively released from infected cells into circulation in HIV positive individuals and can be 
detected in the sera of patients undergoing HAART 110,143 In recent years, numerous studies 
have found that HIV-1 Tat does not exclusively bind to and interact with HIV-1 genes, but also 
to cellular genes and factors, as discussed in Chapter 1. Preliminary data from our research 
group has shown that HIV-1 Tat enhances the promoter activity of c-MYC in a dose-dependent 
manner144. Here, we aimed to confirm this activation and to uncover the mechanisms driving 
it. In silico analyses was employed to identify putative transcription factor (TF) binding 
elements within the ~2 kbp region upstream of the transcription start site (TSS) referred to as 
the full-length (FL) c-MYC promoter. Based on the location of these TF binding sites (TFBS), 
promoter deletion constructs were produced and used in dual-luciferase reporter assays to 
identify the minimal promoter region mediating the activation by HIV-1 Tat.  Thereafter, site-
directed mutagenesis (SDM) was used to interrogate the role of specific TFBS. This was 
followed by co-immunoprecipitation (Co-IP) assays, to identify protein-protein interactions, 







2.2.1 Cell lines and culture conditions  
 
The human HT1080 cell line was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Sigma Aldrich, USA) supplemented with 10% foetal bovine serum (FBS) (Invitrogen, USA) 
and 1% penicillin/streptomycin (Sigma Aldrich, USA). The human BL cell line Ramos was 
used in this study. Ramos is an EBV negative cell line derived from sporadic BL that has been 
widely used in the literature to study this cancer. Ramos cells were obtained from ATCC 
(Manassas, VA) and grown in Roswell Park Memorial Institute (RPMI-1640) media (Sigma 
Aldrich, USA) supplemented with 10% FBS (Sigma Aldrich, USA)  and 1% 
penicillin/streptomycin (Sigma Aldrich, USA)  or 20% FBS post electroporation. Cells were 
incubated in a 5% CO2 humidified incubator at 37°C. Mycoplasma testing was done 
periodically to ensure cells were not contaminated. Testing was done using bisBenzimide H 
33342 trihydrochloride (14533, Sigma Aldrich, USA) DNA staining. 
 
2.2.2 Electroporation of plasmid DNA into BL cells 
 
Ramos cells were counted at the log phase of growth and 4 x 106 cells were transferred to 0.4 
cm electroporation cuvettes at a total volume of 450 μL RPMI-1640 media without 
supplementation. 15 μg of either pcDNA-Tat or pcDNA3.1 empty control (both plasmids were 
kindly donated by Professor Mitra from the National Center for Cell Sciences in India) was 
added to the cuvettes and electroporated using the Gene Pulser Xcell system (Bio-Rad, USA) 
with the following conditions:  exponential wave, 0.28kV and 950 µF. Cells were incubated on 
ice for 10 minutes followed by gentle resuspension and transfer to prewarmed RPMi-1640 
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media supplemented with 20% FBS (Sigma Aldrich, USA) and 1% (Sigma Aldrich, USA) 
penicillin/streptomycin. Cells were incubated for 24-48 hrs before protein was harvested for 
western blot analysis or RNA for qRT-PCR.  
2.2.3 Western blot analyses 
 
Electroporated cells were centrifuged at 1000rpm for 5 minutes followed by two washes in 1x 
PBS (Appendix A). Pelleted cells were resuspended in 2x Laemmli buffer (Appendix A) and 
boiled for 5 min at 95°C. Protein was separated using 12% SDS-PAGE gels (Appendix A), 
transferred to nitrocellulose membranes (Bio-Rad, USA) using the Mini-PROTEAN 3 casting 
apparatus (Bio-Rad). The following antibodies were used to detect target proteins: primary 
antibodies used were anti-c-MYC (SC-764, Santa Cruz Biotechnology, USA; 1:1000) and anti-
p38 (M0800, Sigma-Aldrich, USA; 1:5000). Secondary antibodies used were Goat Anti Rabbit 
(H+L) HRP conjugate (170-6515, Bio-Rad, USA; 1:5000) and Goat Anti Mouse (H+L) HRP 
conjugate (170-6516, Bio-Rad, USA; 1:5000). Densitometric analysis of the signal intensity of 
bands was done using the ImageJ software (NIH, USA). 
 
2.2.4 c-MYC Promoter sequence analysis  
 
The FL promoter (-2324 bp - +537 bp) of the c-MYC gene cloned within the pGL3-Basic 
luciferase reporter vector (kind gift of Professor Xing Dai from the University of California 
USA) was sequenced for verification and analysed using the online tool PROMO 
(Algorithmics and Genetics Group, Universitat Politecnica de Catalunya 
http://alggen.lsi.upc.es/cgibin/prom‐v3/promo/promoinit.cgi? dirDB=TF_8.3) to identify 




2.2.5 Generation of c-MYC promoter deletion constructs 
 
To determine the TF sites responsible for mediating the observed increased promoter activity 
under the effect of HIV-1 Tat, deletion constructs of the c-MYC promoter were designed to 
gradually remove promoter regions using primers with incorporated restriction enzyme sites.  
 
2.2.5.1 Generation of deletion fragments using  PCR 
 
PCR was performed with the MyTaqTM  DNA polymerase kit (Bioline, USA) using forward 
and reverse primers (with incorporated restriction enzyme (RE) sites) using the plasmid 
containing the full-length promoter of the c-MYC gene (pGL3-cMYC kindly donated by 
Professor Hiroyuki Suzuki at the University of Tsukuba, Japan) as the template, to generate 
sequential deletions. Primers used to generate deletion constructs are listed in Table 2.1 with 
inserted RE sites underlined and in bold. PCR conditions are listed in Table 2.2.  
 
Table 2.1: c-MYC promoter cloning primers. 
Primer Sequence  Tm  GC% RE site 










Forward 3 5’-CTAGAGCGAGCTCGCTCGGCTGCC-3’ 
 
62.3°C                                                        62.5% SacI










Table 2.2: PCR cycling conditions.  
Program Temperature Time  Cycles 
Initial denaturation 95°C 1 min 1 
Denaturation 95°C 15 sec  
30 Annealing 54°C 15 sec 
Extension 72°C 40 sec 
Final extension 72°C 8 min 1 
 
 
2.2.5.2 Restriction enzyme digest 
 
To incorporate the deletion fragments into the pGL3 Basic plasmid, the PCR products were 
first ligated into the p-GEM-T-Easy (Promega, USA) plasmid to facilitate restriction enzyme 
digestion. The pGEM-T-Easy plasmids with the shortened promoter inserts and the pGL3 Basic 
plasmid were digested with the SacI (GAGCTC) and HindIII (AAGCTT). Digested fragments 
were then electrophoresed on a 1% agarose gel (Appendix A) at 70V for 1 hour. The bands of 
interest were cut out of the gel, purified using the MinElute Gel extraction kit (Qiagen, 
Germany) and quantified using the Nanodrop1000 (Thermo Fisher Scientific, USA).  
 
2.2.5.3 Promoter fragment ligation within pGL3 Basic vector 
 
Promoter fragments were ligated within the linearized pGL3 Basic plasmid using T4 ligase 
(Promega, USA). A molar ratio of 4:1 (insert to vector) was used in the ligation and the reaction 





𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 × 𝐾𝑏𝑝 𝑖𝑛𝑠𝑒𝑟𝑡
𝐾𝑏𝑝 𝑣𝑒𝑐𝑡𝑜𝑟  
 
2.2.5.4 Competent bacterial cells 
 
E. coli (strain DH5α) cells were made competent using the CaCl2 method 147. Briefly, bacterial 
cells were grown in 200 mL lysogeny broth (LB) (Appendix A) for 3 hrs until the culture 
reached an O.D of 0.5-0.8. Cells were then pelleted at room temperature (RT) and resuspended 
in 30 mL of ice-cold 100 mM CaCl2 (Appendix A), followed by incubation on ice for an hour. 
The cells were then pelleted at 4°C and resuspended with 1 mL of ice-cold 100 mM CaCl2 and 
stored at 4°C for up to two weeks or stored at -80°C for long term storage with the inclusion 
of 25% sterile glycerol. 
 
2.2.5.5 Bacterial transformation and colony PCR 
 
The propagation of ligated pGL3 plasmids was done through bacterial transformation and 
expansion according to protocols outlined in Sambrook et al (2001). Briefly, the ligation 
reaction was added directly to 100 µL of competent cells and incubated on ice for 30 min 
followed by heat-shocking at 37°C for 5 min. Transformed bacterial cells were then allowed 
to grow in 500 µL of LB broth 2 hrs at 37°C  with gentle agitation. The transformed cells were 
thereafter plated on LB Agar plates (Appendix A) containing ampicillin (100mg/ml) and 
incubated overnight at 37°C. To test for positive transformants, colony PCR was performed 
using MyTaqTM DNA polymerase (Bioline, USA) and vector-specific primers (Table 2.3) 





Table 2.3: pGL3 Basic specific primers used in colony PCR. 
Primer Sequence (5’-3’) Tm  
RVprimer3 5’-CTAGCAAAATAGGCTGTCCC-3’                             53°C                                                        
GLprimer2  5’-CTTTATGTTTTTGGCGTCTTCCA-3’ 55°C                                                        
 
 
Table 2.4: Colony PCR cycling conditions. 
Program Temperature Time  Cycles 
Initial denaturation 95°C 1 min 1 
Denaturation 95°C 15 sec  
30 Annealing 47°C 15 sec 
Extension 72°C 40 sec 
Final extension 72°C 8 min 1 
 
 
2.2.5.6 Plasmid isolation from bacterial cells 
 
The purifications of plasmids were done using the PureYield™ Plasmid Maxiprep System 
(Promega, USA). Briefly, 200 mL of LB broth was inoculated with a 1 mL overnight DH5α 
culture carrying the plasmids of interest. The 200 mL of LB broth (Appendix A) was incubated 
at 37°C overnight in gentle agitation. Following incubation, cells were pelleted at 3000 rpm 
for 10 min at RT and the PureYield™ Plasmid Maxiprep System (Promega, USA) was used to 
isolate pure and endotoxin-free plasmids. These were quantified using a Nanodrop1000 and 
the plasmid integrity assessed using gel electrophoresis.  
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2.2.6 Dual-luciferase reporter assays  
 
Dual-luciferase reporter assays were conducted in HT1080 cells seeded at a density of 5x 104 
cells/mL in 6-well cell culture dishes. 400 ng of each luciferase reporter construct (full length 
(pGL3-cMYC WT) or deletions of the c-MYC promoter) were co-transfected, using X-
tremeGeneTM HP transfection reagent (Sigma Aldrich, USA) with up to 500 ng of pcDNA-Tat 
or the corresponding empty vector (pcDNA3.1 empty) as well as 50 ng the pRL-TK vector, 
kindly provided by Professor Sharon Prince from the University of Cape Town, driving the 
expression of a Renilla reporter (used as a control for transfection efficiency). All transfections 
were done in duplicates and Luciferase assays were repeated at least three times (n=3). Thirty 
(30) hrs post-transfection, whole-cell extracts were assayed for firefly and Renilla luciferase 
activity using the dual-luciferase reporter assay system (Promega, USA). Luciferase activity 
was measured using the GloMax®-Multi+ Luminescence Module (Promega, USA). Luciferase 
values were expressed relative to empty vector control values.  
 
2.2.7 Site-directed mutagenesis 
 
Forward and reverse primers containing the desired DNA base pair modifications (underlined 
and in bold in Table 2.5) were generated to disrupt AP-1 binding sites (Figure 2.1). The KAPA 
HiFi HotStart ReadyMix system (Roche, Germany) was used to amplify the pGL3-cMYC 




Figure 2.1: AP-1 sites on the c-MYC promoter targeted for mutation by SDM. Primers 
were designed to abrogate the two AP-1 sites located at positions -1128 bp and -1375 bp 
relative to the TSS present on the pGL3-cMYC WT plasmid. The resulting constructs were 
used in luciferase assays to determine mutating these sites resulted in the loss of promoter 








Table 2.5: SDM primers used to disrupt AP-1 binding sites on the c-MYC promoter. 
Primer Sequence  Tm  GC% 








AP-1 Mut2 F 5’-CAGAAAAAATTGCGTAGTAGTGAACTAGGAAATTAATGCCTGGAAGGC-3’ 73.2 °C                                                        39.6% 








Table 2.6: SDM PCR cycling conditions. 
Program Temperature Time  Cycles 
Initial denaturation 95°C 3 min 1 
Denaturation 98°C 20 sec  
15 Annealing 70°C 15 sec 
Extension 72°C 8 min 
Final extension 72°C 8 min 1 
 
 
2.2.8 Co-immunoprecipitation assay  
 
HT1080 cells (5 x 104 /mL) were plated in 6-well cell culture plates. After 24 hrs, the cells were 
co-transfected with 500 ng of pcDNA-Tat and 500 ng pCMV-JunB plasmids with the 
XtremeGene-HP reagent (Sigma Aldrich, USA) using a 1:3 ratio of DNA (ng) to transfection 
reagent (μL) respectively. Cells were harvested after 24 hrs and lysed using RIPA buffer 
(Appendix A) with protease combined with 7x complete™, Mini, EDTA-free, Protease 
Inhibitor (Roche, Switzerland). Cell lysates were incubated overnight at -80 °C to optimize 
lysis. The following day cell lysates were thawed on ice and the protein fraction was isolated 
by removal of cell debris using centrifugation at 12000 xg for 10 min at 4°C. Protein samples 
were precleared with 50 μL protein A agarose beads (Roche, Switzerland) for 3 hrs at 4°C. the 
Pierce® BCA Protein Assay kit (Thermo Fisher Scientific, USA) was used to quantify the 
protein and 200 μg of protein was used per pulldown. 2 μg of primary antibody (anti-JunB (SC-
8051, Santa Cruz Biotechnology, USA), anti-HIV-1 Tat (NIH AIDS reagent program (2A4.1 
4373) or ab43014, Abcam, UK) and negative control IgG (170-6515, Bio-Rad, USA ) were 
each added to individual tubes containing the 200 μg of the protein and incubated overnight at 
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4°C. The following day 50 μL protein A agarose beads were added to the protein-antibody 
complexes and incubated for 4 hrs at 4°C. Beads were collected by centrifugation at 2000 rpm 
and washed twice in ice-cold 1x PBS (Appendix A) containing protease inhibitors. Beads were 
resuspended in 2x Laemmli buffer (Appendix A) and boiled for 5 min at 95°C followed by 
SDS-PAGE (Appendix A) separation and western blot analysis as outlined in section 2.2.3, 
with appropriate antibodies. 
 
2.2.9 Chromatin Immunoprecipitation assays 
 
HT1080 cells (5 x 104 /mL) were plated in 6-well cell culture plates. After 24 hrs, the cells were 
co-transfected with 500 ng of pcDNA-Tat and 500 ng of pCMV-JunB plasmids with the 
XtremeGene-HP reagent (Sigma Aldrich, USA) using a 1:3 ratio of DNA (ng) to transfection 
reagent (μL) respectively. The DNA was cross-linked using 1% formaldehyde for 10 min at 
RT, quenched with 125 mM glycine (Appendix A) for 5 min at RT. Cells were centrifuged at 
2000 xg for 5 min at 4°C and resuspended in 15 mL ice-cold 1x PBS (Appendix A), 
centrifugation was repeated as before and cells were resuspended in 1.5 mL ice-cold 1x PBS. 
Cells were centrifuged at 1500 xg for 5 min at 4°C and washed in 1 mL NCP buffer I (Appendix 
A), centrifuged again followed by a wash in 1 mL NCP buffer II (Appendix A). Cells were 
pelleted as before and resuspended in ChIP lysis buffer with protease inhibitors (Appendix A) 
and allowed to lyse on ice for 10 min. The lysate was sonicated to obtain chromatin fragments 
between 300-500 bp in length (as assessed by gel electrophoresis). 480 μL of Sonicated DNA 
was added to 1 mL of RIPA buffer containing protease inhibitors (Appendix A) and cleared 
with 90 μL protein A agarose beads (Roche, Germany) for 4 hrs at 4°C in an orbital shaker. 
The precleared lysate was split into equal amounts in individual 1.5 mL Eppendorf tubes each 
containing 2 μg of the appropriate primary antibody (anti-JunB (Santa Cruz Biotechnology, 
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USA), anti-HIV-1 Tat (Abcam, UK) and negative control IgG (Bio-Rad, USA) and were 
incubated overnight at 4°C in an orbital shaker. 50 μL of protein A agarose beads were added 
to each tube and incubated at 4°C in an orbital shaker for 3 hrs. Beads were collected by 
centrifugation at 2000 xg for 5 min and washed with wash buffers 1-4 (Appendix A), twice for 
each buffer, in  4°C in an orbital shaker for 10 min. DNA bound by antibodies was extracted 
by incubation in Extraction buffer (Appendix A) for 15 min at RT followed by overnight 
incubation at 65°C. DNA was then purified using Phenol-chloroform extraction148. DNA 
enrichment was analysed through qRT-PCR on the Rotor Gene-Q (Qiagen, Germany) using 
the 2x QuantiTect SYBR Green PCR Master Mix (Qiagen, Germany).  c-MYC promoter-
specific primers were used (outlined in Table 2.7) with the PCR cycling conditions in Table 
2.8. 
 
Table 2.7: ChIP primers. 
Primer Sequence  Tm  GC% 
Set 1 F 5’-GGAATTAAACGTCCGGTTTGTC-3’ 55.9°C  52.4% 
Set 1 R 5’- GGCAAGTGGAGAGCTTGTG-3’ 55.4°C  55.6% 
Set 2 F 5’- GCAACTAGCTAAGTCGAAGCG-3’ 54.4°C  45.5% 











Table 2.8: ChIP qRT-PCR cycling conditions. 
Program Temperature Time   
Initial denaturation 95°C 3 min 1 
Denaturation 95°C 5 sec 40 
Annealing/extension 55°C 20 sec 
Final extention 55°C 8 min 1 
  
 
2.2.10 Statistical analyses 
 
Student’s t-tests and one-way analysis of variance (ANOVA) tests were used. Significance was 
accepted at p <0.05, Tukey’s post hoc test was done for multiple comparisons. Statistical 
significance was determined using the GraphPad PRISM version 7 for Windows, GraphPad 














2.3 Results  
 
2.3.1 HIV-1 Tat enhances the activity of the FL c-MYC promoter and increases c-MYC 
protein expression in the BL cell line Ramos 
 
Previous preliminary work done in the laboratory had shown that HIV-1 Tat can increase the 
activity of the full-length c-MYC promoter in a dose-dependent manner 144. To confirm this 
preliminary finding, the luciferase reporter assays were repeated. A significant increase, of 
more than 3 folds, in the activity of the promoter was observed in the presence of HIV-1 Tat 
when compared to the control (Figure 2.2A) confirming the previous results. To determine if 
the observed increase in c-MYC promoter activity, due to HIV-1 Tat, translates to an increase 
in the protein expression level, western blot analysis was performed in the BL cell line Ramos 
in which HIV-1 Tat was ectopically expressed. Due to the recalcitrant nature of these cell lines 
to conventional transfection techniques using commercially available transfection reagents, 
electroporation was utilised to deliver plasmid DNA into the cells. Ramos cells were 
electroporated with either pcDNA-Tat or pcDNA3.1 empty control vectors and protein was 
harvested 24 hrs post-electroporation. Western blot analysis showed that Ramos cells 
expressing HIV-1 Tat had elevated c-MYC protein expression compared to control (Figure 
2.2B). To ensure that plasmid delivery was being achieved, the cells were also independently 
electroporated with the pEGFP-N3 vector, a plasmid that constitutively expresses EGFP, as a 
positive transfection control using the same parameters and plasmid concentrations as in the 
pcDNA-Tat electroporation. The expression of EGFP was indeed detected in the cells, albeit 











Figure 2.2: Luciferase reporter assay confirming that HIV-1 Tat enhances the activity of 
the c-MYC WT promoter and western blot showing increased c-MYC protein in BL cells 
expressing HIV-1 Tat. A) HT1080 cells were transfected with 500 ng of the c-MYC WT 
promoter (pGL3-c-MYC) along with 400 ng of the HIV-1 Tat expression vector (pcDNA-Tat) 
or 400 ng of the pcDNA3.1 empty vector as control. Fold activation was obtained by comparing 
the relative luciferase units (RLU) of the HIV-1 Tat transfected groups to their empty 
transfected controls. Statistical analysis was done using GraphPad PRISM 7 with a two-tailed 
Student’s t-test. This experiment was performed at least in triplicate. B) Ramos cells were 
electroporated with either 15 µg pcDNA-Tat or 15 µg pcDNA3.1 empty vector control. Protein 
was harvested and western blot was done using anti-c-MYC antibody and the anti-p38 antibody 
as a loading control. The bar graph represents densitometric analysis (ImageJ).  Fold increase 
was obtained by comparing the relative densitometric units of the HIV-1 Tat electroporated 
cells to the negative control cells, which were set to 1, after normalising to loading control 
(p38). Western blot is representative of at least two independent experiments. C) EGFP 
expressing cells. Ramos cells were electroporated with 15 µg of the pEGFP-N3 plasmid to 
serve as a positive control for electroporation. D) Phase contrast of the same field of vision as 
C. Scale bars represent 200 µm. 
 
2.3.2 PROMO analysis identifies multiple putative TFBS within the c-MYC promoter 
 
Using the online software PROMO, a comprehensive analysis of the FL c-MYC promoter was 
performed to identify putative transcription factor binding sites (TFBS) 145,146. A dissimilarity 
rate was set at 15% to not dismiss potential binding sites. TFs with previously reported 
associations, directly or indirectly, with HIV-1 Tat, or which have been implicated in BL 
pathobiology were annotated. Sites were mapped onto the promoter sequence and the result is 
displayed in Figure 2.3. This analysis was done to identify TFBS which may potentially 
mediate the response observed in Figure 2.2A and to guide in the development of the sequential 
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Figure 2.3: Putative transcription factor binding sites located within the c-MYC FL promoter, as identified using the PROMO software. 
The FL c-MYC promoter (-2324 bp to +537 bp) construct was analysed for TFBS using PROMO.  Sites are represented as different coloured 
shapes which are labelled in the key and the transcription start site (TSS) is denoted by a black arrow. Sequential deletion constructs were designed 
to remove specific TFBS. Shortened promoter constructs are labelled accordingly on the right side of the diagram (pGL3-cMYC-DF1, pGL3-




2.3.3 HIV-1 Tat enhances the c-MYC promoter activity via AP-1 binding sites. 
 
HIV-1 Tat’s ability to directly or indirectly interact with the promoter regions of host genes 
has been described in the literature 132,133. To identify the minimal promoter region required for 
HIV-1 Tat-mediated promoter activation three sequential promoter deletion constructs were 
generated using the full-length c-MYC promoter as a template, with each deletion resulting in 
loss of specific TF binding sites (Figure 2.3). Luciferase assays were performed using the full-
length and deletion constructs and it was observed that the loss of the region spanning -1494 
bp to -969 bp (pGL3-cMYC-DF2 construct) led to a significant reduction in promoter 
activation in the presence of HIV-1 Tat (Figure 2.4A). A loss of 35% in activity was observed 
from 2.6-fold in WT to 1.7-fold in the DF2 construct. Additionally, when compared to the 
empty control, the promoter activities of both the DF2 and DF3 constructs were not 
significantly higher than the WT and DF1 constructs.  
 
The region spanning -1494 bp to -969 bp contains two AP-1 sites as well as one p53 and one 
E2F site. Further inspection revealed that the two AP-1 sites (AP-1 site 1 at position -1128 and  
AP-1 site 2 at position -1375) had favourable dissimilarity scores indicating that these sites are 
potentially functional in vivo, with site 2 being previously reported to induce c-MYC 
transcription upon Platelet-Derived Growth Factor (PDGF) receptor stimulation 149.  
Furthermore, the AP-1 factor c-Jun has been shown to enhance the HIV-1 Tat-mediated 
transcription of the viral LTR 150. These observations provided confidence that AP-1 sites 1 
and/or 2 could be relevant in mediating the promoter activation. To test this, SDM was used to 
sequentially mutate these sites, as well as in combination. Luciferase assays were then repeated 
using FL, WT and mutated constructs. A significant loss in promoter activity of ~20% was 
observed when AP-1 site 1 was mutated (Figure 2.4B) and ~25% when AP-1 site 2 was 
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mutated (Figure 2.4C). Furthermore, when both sites were simultaneously abolished, a 
decrease of ~29% was observed (Figure 2.4C). These results indicated that indeed, HIV-1 Tat-

































Figure 2.4: The AP-1 sites located at positions -1128 bp and -1375 bp partially mediate 
the HIV-1 Tat enhancement of c-MYC promoter activity. A) Luciferase reporter assay 
comparing the fold activation of the c-MYC WT promoter to the deletion constructs (DF1-DF3) 
in the presence of HIV-1 Tat. HT1080 cells were transfected with 500ng of the c-MYC WT 
promoter (pGL3-cMYC) or deletion constructs (pGL3-cMYC-DF1, pGL3-cMYC-DF2 and 
pGL3-cMYC-DF3) along with 400ng of the HIV-1 Tat expression vector (pcDNA-Tat) or 
400ng of the empty pcDNA3.1 as control. B) Luciferase assay comparing fold activation in the 
presence of HIV-1 Tat between the WT promoter, DF2 and AP-1 MT1 constructs. C) Luciferase 
assay comparing fold activation in the presence of HIV-1 Tat between the WT promoter, AP-1 
MT2 and AP-1 MT1+2 constructs.  Fold activation was obtained by comparing the relative 
luciferase units (RLU) of the pcDNA-Tat transfected groups to their empty transfected controls, 
which were set to 1. AP-1 mutated sites are represented as striated blocks. Statistical analysis 
was done using one-way ANOVA in GraphPad PRISM 7. Significance *(p<0.05), **(p<0.005) 
and ns (not significant). The graphs are representative of at least three separate repeats. 
 
2.3.4 Co-immunoprecipitation assay demonstrates strong protein to protein interaction 
between HIV-1 Tat and the AP-1 factor JunB 
 
Previous studies have shown that HIV-1 Tat can form complexes with cellular proteins 
including transcription factors. For instance, HIV-1 Tat was found to form a complex with 
NFAT and c-Jun at an NFAT/AP-1 composite site 151. In the context of this study, whether 
HIV-1 Tat mediates its effect through direct binding and/or interaction with cellular 
transcription factors, is not known. However, there is evidence in the literature that supports 
both scenarios 135,152. To investigate whether HIV-1 Tat can form a complex with AP-1 factors, 
a co-immunoprecipitation assay was performed, where HT1080 cells were transfected with 
pcDNA-Tat and pCMV-JunB expression constructs. The Jun family of proteins are a major 
component of AP-1 complexes and have been associated with HIV-1 Tat 150,153,154. A pull-
down assay was performed using antibodies specific to HIV-1 Tat or JunB followed by western 
blot analyses. The result indicates that HIV-1 Tat can form strong associations with JunB as 
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the protein was detected in an immunoprecipitation assay where an HIV-1 Tat specific antibody 
was used to pull down proteins followed by a western blot with JunB antibody (Figure 2.5A). 
Similarly, HIV-1 Tat was detected in an immunoprecipitation assay where the JunB specific 
antibody was used to pull down proteins followed by a western blot with an HIV-1 Tat 
antibody. However, in this case, HIV-1 Tat was detected in the negative control sample (Figure 
2.5B). The Co-IP was repeated with a different HIV-1 Tat antibody (ab43014, Abcam, UK) to 
eliminate the positive HIV-1 Tat signal observed in the IgG pulldown in Figure 2.5B. The 
HIV-1 Tat pulldown with the ab43014 antibody successfully enriched the JunB protein (Figure 
2.5C), however when performing the pulldown with JunB antibody and a western blot with the 
ab43014 antibody, no HIV-1 Tat protein could be detected (Figure 2.5D). These results 
indicate that the JunB antibody, while competent in western blot assays, is not compatible with 
immunoprecipitation. Nevertheless, we found confidence in this result by the fact that two 
independent anti-Tat antibodies were able to successfully pull down JunB in separate assays 













Figure 2.5: Co-immunoprecipitation assay shows binding between HIV-1 Tat and AP-1 
factor JunB. HT1080 cells were transfected with both 500 ng HIV-1 Tat expression vector 
(pcDNA-Tat) and 500 ng JunB expression vector (pCMV-JunB). A&C) The cell lysate was 
incubated with anti-HIV-1 Tat antibody (Aids reagent program, NIH, USA used in A or 
ab43014, Abcam, UK used in C) and pulled down using protein A agarose beads (Roche, 
Germany). Western blot was carried out using an anti-JunB antibody (Santa Cruz, USA) to 
detect JunB in the HIV-1 Tat pull-down. B&D) The cell lysate was incubated with anti-JunB 
antibody (Santa Cruz, USA) and pulled down using protein A agarose beads (Roche, Germany). 
Western blot was carried out using an anti-HIV-1 Tat antibody (Aids reagent program, NIH, 
USA used in B or ab43014, Abcam, UK used in D) to detect HIV-1 Tat in the JunB pull down. 
In both western blots, the goat-anti-rabbit secondary antibody (Bio-Rad, USA) was used as a 








2.3.5 Chromatin immunoprecipitation reveals JunB and HIV-1 Tat occupancy at the 
AP-1 sites on the c-MYC promoter 
 
To determine if the identified AP-1 sites were indeed functional and if JunB was able to bind 
these sites in vivo in the presence of HIV-1 Tat, ChIP assay with primers designed to amplify 
regions of the promoter that harbour the previously identified AP-1 sites were performed. The 
results show that both sites were enriched when pulling down with JunB antibody with a 
significantly pronounced enrichment found in AP-1 site 2. HIV-1 Tat binding to site 2 was also 
detected but at a lower level, and although not statistically significant, the result was 


















Figure 2.6: HIV-1 Tat and JunB proteins associate with the c-MYC promoter at AP-1 
binding sites. Diagrammatic representation of the c-MYC promoter depicting the location of 
the two AP-1 sites in square blocks and the positions of the forward and reverse primers used 
for the ChIP assay are denoted by black arrows. Bar graphs show qRT-PCR data using 
immunoprecipitated DNA obtained from ChIP with either anti-JunB, anti-HIV-1 Tat or anti-
IgG (negative control) antibodies and amplified with the primers depicted in the diagram 
Statistical significance determined using Student’s t-test in GraphPad PRISM 7, 





HIV-1 infection has been associated with the development of multiple cancers. Amongst these 
BL and DLBCL are particularly enriched in the HIV positive population 155,156. Recent studies 
have brought attention to the oncogenic potential of HIV-1 and its associated proteins in 
promoting these cancers, however, the molecular mechanism driving these phenomena is as 
yet poorly defined. In this aspect of the study, we sought to establish the mechanism via which 
HIV-1 Tat influences the promoter activity of c-MYC.  While overexpression of c-MYC in BL 
is primarily ascribed to its translocation to the IgH loci, hardly any studies have been performed 
on assessing any changes in expression of the intact c-MYC allele. Within the context of HIV-
associated BL, this is particularly relevant since this subtype is more aggressive than the eBL 
and sBL subtypes, despite all three being considered as the same pathological entity. 
 
The results presented here confirm preliminary assessments from our research group that the 
activity of a ~2 kbp promoter fragment of the c-MYC gene is enhanced in the presence of HIV-
1 Tat.  These findings are supported by work done by Germini et al (2017), where the authors 
showed that B cells exposed extracellularly to recombinant HIV-1 Tat protein had increased c-
MYC mRNA expression139. The affinity of HIV-1 Tat for promoter regions of host genes has 
been described in the context of T-cell infection. Genome-wide studies have revealed that HIV-
1 Tat binds to a variety of regions within the human T cell genome 132–134. Notably, in Jurkat 
cells (acute T cell leukaemia cell line), HIV-1 Tat was found to preferentially occupy promoter 
and 5’-UTR regions in Jurkat cells. Importantly, these associations were conserved in RNA-
Seq data showing that HIV-1 Tat not only binds to but also alters host gene expression, 
specifically genes involved in the cellular immune response. Other studies have shown that 
HIV-1 Tat forms protein-to-protein interactions with host TFs, including AP-1 factors, and 
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augments their binding to promoters of host genes 122,135,157. Using promoter deletion luciferase 
reporter assays and SDM, we found that two AP-1 binding sites within the c-MYC promoter 
are important in mediating the HIV-1 Tat-dependent promoter increase. Of note, site 2 has 
previously been implicated in c-MYC promoter activation via observed binding of c-Jun and 
JunD, however, JunB demonstrated weak binding by EMSA and no binding by ChIP 149, 
contrary to what was observed in the dual-luciferase and ChIP assays performed in this study 
(Figure 2.4 and Figure 2.6 respectively). Furthermore, Co-IP showed that JunB and HIV-1 
Tat form strong protein-to-protein interactions and ChIP assays demonstrated that JunB, in the 
presence of HIV-1 Tat, occupied the c-MYC promoter at both AP-1 binding sites with the 
highest enrichment shown at site 2. It is important to note that a complete decrease in fold 
activation was not observed with the promoter deletions or AP-1 site mutations, this could be 
due to other active sites compensating for the loss of the AP-1 sites, coupled with the potential 
promiscuous binding of HIV-1 Tat to the promoter. Future work is needed to clarify whether 
HIV-1 Tat utilizes other sites within the c-MYC promoter besides the two identified AP-1 sites.  
 
Given that the activation of AP-1 factors through phosphorylation occurs downstream of the 
JNK pathway, it is plausible that HIV-1 Tat induces the JNK pathway directly, thereby 
increasing AP-1 factor binding to the c-MYC promoter. The effect of HIV-1 Tat on the 
induction of the JNK pathway in both T and B cells has previously been described 153,158. 
Additionally, B cells exposed extracellularly to recombinant HIV-1 Tat have increased ROS 
production which could potentially induce the JNK pathway and lead to increased AP-1 
phosphorylation 110. Interestingly, a positive feedback loop between c-MYC and AP-1 factors 
has been proposed in BL, with increased c-MYC levels leading to increased AP-1 
phosphorylation and binding to the Igκ Ei and E3’ enhancers,  potentially increasing expression 
of translocated c-MYC in Igκ/c-MYC-BL and possibly that of the unaffected allele on 
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chromosome 8 159. The increased transcriptional activity of the c-MYC gene due to HIV-1 Tat, 
coupled to its increased localization to the IgH locus and aberrant AID activity, could lead to 
enhanced proliferation and more aggressive disease in HIV positive people.  
 
HIV-1 Tat binding to the human genome is greater than previously thought, and the regulatory 
role of HIV-1 Tat is not only observed in the viral genome but also in that of the host, with 
these interactions not limited to cells that are actively infected by HIV-1. Therefore, the 
possibility that Tat can lead to oncogenic transformation via altering cellular gene expression 
is significant and needs investigation. This study has shown further mechanistic evidence for 
HIV-1Tat induced c-MYC activation in the context of BL. Further work needs to be done to 
validate these findings in vivo. An interesting avenue for future research would be to determine 
if the observed findings in this study are downstream of the JNK pathway, activated by HIV-1 
Tat. Furthermore, uncovering other interactions between HIV-1 Tat and the B cell genome will 














Chapter 3: The regulation of AICDA/AID 


















AID plays a central role in the development of mature B-cell NHLs and HIV-1 infection has 
been linked to AID deregulation. Epeldegui et al (2007) showed that elevated AID expression 
in the peripheral mononuclear cells (PBMC) of HIV positive patients predated an eventual 
diagnosis of lymphoma. Notably, the most pronounced increase in AID levels was observed in 
patients subsequently diagnosed with BL 160. This, coupled to the fact that HIV-1 proteins like 
HIV-1 Tat and Nef become internalized by bystander cells, including B cells, suggests the 
possibility of direct interference of AICDA/AID regulation by HIV-1 137,161,162. Work done by 
our research group showed that treating the BL cell line Ramos with extracellular recombinant 
HIV-1 Tat induced AID expression at the transcriptional level 144. More recently, Sall et al 
(2019) showed that peripheral blood-derived B cells, from HIV positive patients, incubated 
with HIV-1 Tat recombinant protein had increased H3 acetylation in the promoter region of 
AICDA, indicative of active transcription 163. The mechanism via which HIV-1 Tat leads to this 
increase remains as yet unclear. In a recent study, where the authors investigated the effect of 
HIV-1 Tat on astrocytes in the context of HIV-associated neurocognitive disorders (HAND), 
they found that HIV-1 Tat could inhibit specific cellular microRNAs, one of which was hsa-
miRNA-181b 141. This miRNA has been shown to directly bind to and repress the murine Aicda 
3’UTR, and the expression of hsa-miRNA-181b was shown to be lower in BL  as compared to 
human normal primary B cells 142. This study therefore aimed at identifying the molecular 
interactions between HIV-1 Tat and the regulatory mechanism governing AICDA/AID 
expression at the transcriptional and posttranscriptional levels. To this end, the R1 promoter 
region was analysed for potential TFBS and sequential deletion constructs of the promoter were 
generated. Dual-luciferase assays were done using the full length (2141 bp) and deletion 
constructs of the R1 promoter, cloned upstream of the pGL3 luciferase reporter vector, in the 
60 
 
presence of HIV-1 Tat. AICDA transcription is also regulated by the R2 and R4 regions, 
therefore, dual-luciferase assays were also performed using these regulatory regions to further 
test if HIV-1 Tat alters their activity. Western blot was done to determine if the reported HIV-
1 Tat-mediated increase of AICDA transcription was conserved at the protein level in BL cells 
and if increased levels of AID protein resulted in alterations to genomic stability as a result of 
AID perturbation. Furthermore, to investigate whether HIV-1 Tat is also involved in the post-
transcriptional regulation of AID, via hsa-miRNA-181b-5p perturbation, electroporation of the 
BL cell line Ramos was performed followed by qRT-PCR to evaluate changes in hsa-miRNA-
181b-5p expression. Lastly, dual-luciferase reporter assays were done to validate the repressive 

















3.2.1 Cell lines and culture conditions 
 
The Ramos and the HT1080 cell lines were cultured using the same methodology as described 
in Chapter 2 section 2.2.1.  
 
3.2.2 AICDA R1 Promoter sequence analysis  
 
The FL promoter (2141 bp) of the AICDA gene was sequenced followed by analysis using the 
online tool PROMO (Algorithmics and Genetics Group, Universitat Politecnica de Catalunya 
http://alggen.lsi.upc.es/cgibin/prom‐v3/promo/promoinit.cgi? dirDB=TF_8.3) to identify 
potential TF binding sites 145,146.  
 
3.2.3 Generation of AICDA R1 promoter deletion constructs  
 
To determine the TF sites responsible for mediating the observed increased promoter activity 
under the effect of HIV-1 Tat, deletion constructs of the AICDA R1 promoter were designed to 
gradually remove promoter regions using primers with incorporated restriction enzyme sites. 
 
3.2.3.1 Promoter fragment PCR 
 
PCR was performed using forward and reverse primers (with incorporated restriction enzyme 
sites) using the plasmid containing the full-length R1 promoter of the AICDA gene as a 
template, to generate sequential deletions. Primers designed are listed in Table 3.1, with 
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inserted RE sites underlined and in bold. PCR conditions used to generate the shortened 
promoter constructs are listed in Table 3.2.  
 
 
Table 3.1: AICDA R1 promoter cloning primers. 
Primer Sequence Tm  GC% RE site 
Forward 1 5’-GCTATATTCTGGAACGCGTGATAACAGG-3’                             62.1°C                                                        46.4% MluI
Forward 2  5’-CTCTTGCCTACGCGTATGTAAGATG-3’                             58.2°C                                                      48% MluI
Forward 3 5’-GTACTGACGCGTAGAGAGACTGTGG-3’                             61.5°C                                                    56% MluI
Forward 4 5’-GAAGGGCACGCGTACTGTCAGACTAAG-3’                             60.8°C 55.6% MluI 
Reverse  5’-CTGTCCAAAGCTTTGTCCAGAGTGTC-3’                             60.7°C                                                        50% HindIII
 
 
Table 3.2: PCR cycling conditions. 
Program Temperature Time  Cycles 
Initial denaturation 95°C 1 min 1 
Denaturation 95°C 15 sec  
30 Annealing 54°C 15 sec 
Extension 72°C 40 sec 






3.2.3.2 Restriction enzyme digest 
 
To incorporate the deletion fragments into the pGL3 Basic plasmid, the PCR products were 
ligated into the p-GEM-T-Easy (Promega, USA) plasmid to facilitate restriction enzyme 
digestion. The pGEM-T-Easy plasmids with the shortened promoter inserts and the pGL3 Basic 
plasmid were digested overnight at 37°C using the MluI (ACGCTG) and HindIII (AAGCTT). 
Digested fragments were then electrophoresed on a 1% agarose gel (70V, 1 hour) stained with 
ethidium bromide (0.5 μg/mL). Fragments were then isolated from the gel and purified using 
the MinElute Gel extraction kit (Qiagen, Germany) and quantified using the Nanodrop1000.  
 
3.2.3.3 Promoter fragment ligation within pGL3 Basic vector 
 
The same methodology was used as described in Chapter 2 section 2.2.5.3. 
 
3.2.3.4 Competent bacterial cells 
 
The same methodology was used as described in Chapter 2 section 2.2.5.4. 
 
3.2.3.5 Bacterial transformation and colony PCR 
 
The same methodology was used as described in Chapter 2 section 2.2.5.5. 
 




The same methodology was used as described in Chapter 2 section 2.2.5.6. 
 
3.2.4 Dual-luciferase reporter assays 
 
 
Dual-luciferase reporter assays were conducted in HT1080 cells seeded at a density of 5x104 
cells/mL in 6-well cell culture dishes. 400 ng of each luciferase reporter construct [full length 
(pGL3-AICDA-R1 – previously cloned in our laboratory), deletions of the AICDA  R1 
promoter, AICDA R2 (pGL3-AICDA-R2) or AICDA R4 (pGL3-AICDA-R4) regulatory 
region] were co-transfected, using X-tremeGeneTM HP transfection reagent (Sigma Aldrich, 
USA) with up to 500 ng of pcDNA-Tat or the corresponding control vector (pcDNA3.1 empty) 
as well as 50 ng of the pRL-TK vector, kindly provided by Professor Sharon Prince from the 
University of Cape Town, driving the expression of a Renilla reporter (used as a control for 
transfection efficiency). All transfections were done in duplicates and Luciferase assays were 
repeated at least three times (n=3). Thirty (30) hrs post-transfection, whole-cell extracts were 
assayed for firefly and Renilla luciferase activity using the dual-luciferase reporter assay 
system (Promega, USA). Luciferase activity was measured using the GloMax®-Multi+ 
Luminescence Module (Promega, USA). Luciferase values were expressed relative to empty 
vector control values.   
3.2.5 Electroporation of plasmid DNA into B cells 
 







3.2.6 miScript qRT-PCR  
 
3.2.6.1 Total RNA isolation 
 
Total RNA was isolated using the AllPrep DNA/RNA/miRNA universal kit (Qiagen, 
Germany). Electroporated cells were centrifuged at 1000 rpm for 5 min to pellet cells. Pelleted 
cells were resuspended in 1x PBS (Appendix A) and centrifuged again at 1000rpm for 5 min. 
Cells were resuspended and lysed in 600 µL RLT buffer (Qiagen, Germany) supplemented 
with β-Mercaptoethanol (10µL/mL). Homogenization of the cell lysate was performed by 
passing lysate through a sterile 20-gauge needle. The homogenized lysate was then transferred 
to the AllPrep DNA Mini spin column and centrifuged at 16000 x g for 30 sec. The flow-
through, containing the RNA, was treated with 80 µL of Proteinase K (Qiagen, Germany) and 
350 µL 99% ethanol for 10 min at RT. 750 µL 99% ethanol was added and the mixture was 
centrifuged through the RNeasy mini spin column at 16000 x g for 30 sec. Flow-through was 
discarded and 500 µL RPE buffer (Qiagen, Germany) was added to the column and centrifuged 
at 16000 x g for 30 sec. DNase I incubation mix containing 10 uL DNase I and 70 µL RDD 
buffer (Qiagen, Germany) was added to the column and incubated for 15 min at RT followed 
500 µL FRN buffer (Qiagen, Germany) and centrifuged at 16000 x g for 30 sec. Flow-through 
was returned to the column and centrifuged again. 500 µL of buffer RPE was added and 
centrifuged as before. An ethanol wash was done with 500 µL of 99% ethanol and centrifuged 
as before. An additional centrifugation step was done to remove residual ethanol (centrifuged 
at 16000 x g for 2 min). Total RNA was eluted into diethyl pyrocarbonate (DEPC) treated 





3.2.6.2 cDNA synthesis and qRT-PCR  
 
cDNA was generated from 100ng isolated total RNA using the miScript II RT kit (Qiagen, 
Germany). Briefly, the 5x HiSpec buffer was used in a total reaction volume of 20 µL. Reaction 
mixes were incubated at 37°C for 60 min followed by 5 min at 95°C.  The resulting cDNA was 
diluted in 100 µL with nuclease-free H2O and aliquoted for storage at -80°C.  qRT-PCR was 
done using the Rotor Gene-Q (Qiagen, Germany) machine with the 2x QuantiTect SYBR 
Green PCR Master Mix (Qiagen, Germany) with cycling conditions outlined in Table 3.3. The 
primers used are listed in Table 3.4. The human snRNA RNU6B was used as an internal PCR 
control. Comparative delta-delta CT method was used for data analysis and presentation. 
 
Table 3.3: miScript qRT-PCR cycling conditions. 
Program Temperature Time  Cycles 
PCR initial activation step 95°C 15 min 1 
Denaturation 94°C 15 sec  
40 
Annealing 55°C 30 sec 
Extension 70°C 30 sec 
 
 
Table 3.4: miScript qRT-PCR primers. 
Primer Qiagen catalogue number 
miScript Universal Primer 218073    
Hs_miR-181b_1 miScript primer assay 218300 MS00006699 
Hs_RNU6-2_1(RNU6B) miScript Primer Assay 218300 MS00033740 
67 
 
3.2.7 AICDA 3’UTR dual-luciferase reporter assay 
 
HT1080 cells were seeded at 0,8 x 105 cells/mL in wells of a 24-well cell culture plate and 
incubated until they reached 70% confluency. Per well, cells were transfected with 350 ng 
luciferase reporter construct containing the full-length AICDA 3’UTR sequence (2182 bp) 
cloned downstream of the luciferase gene in the pGL3-Promoter vector (Promega, 
Switzerland), 50 ng of the pRL-TK used as an internal control for transfection efficiency and 
50nM of the miRNA-181b-5p mimic. The Dharmacon siRNA and Allstar siRNA negative 
controls were used at the same concentration as the miRNA-181b-5p mimic in separate 
experiments. Attractene Transfection Reagent (Qiagen, Germany) was used for the DNA-RNA 
dual transfection, using 1.5uL of Attractene per well. Cells were incubated for 24hrs post-
transfection and whole-cell extracts were assayed for firefly and Renilla luciferase activity 
using the dual-luciferase reporter assay system (Promega, Switzerland). Luciferase activities 
were measured using the GloMax®-Multi+ Luminescence Module (Promega, Switzerland). 
Firefly luciferase values were normalized to the Renilla luciferase activity and expressed 
relative to empty vector control. 
 
3.2.8 Western blot analyses 
 
Electroporated cells were centrifuged at 1000rpm for 5 minutes followed by two washes in 1x 
PBS. Pelleted cells were resuspended in 2x Laemmli Blue buffer (Appendix A) and boiled for 
5 min at 95°C. Protein was separated using 12% SDS-PAGE gels (Appendix A), transferred to 
nitrocellulose membranes (Bio-Rad, USA) using the Mini-PROTEAN 3 casting apparatus 
(Bio-Rad). Primary antibodies used were anti-AID (39-2500, Thermofisher, USA; 1:1000); 
anti-γH2AX (2577, Cell Signalling, US; 1:1000); and anti-p38 (M0800, Sigma-Aldrich; 
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1:5000). Secondary antibodies used were Goat Anti Rabbit (H+L) HRP conjugate (170-6515, 
Bio-Rad, USA; 1:5000) and Goat Anti Mouse (H+L) HRP conjugate (170-6516, Bio-Rad, 
USA; 1:5000) Densitometric analysis of the signal intensity of bands was done using the 





















3.3.1 HIV-1 Tat induces the activity of the AICDA R1 promoter 
 
Previous preliminary work done in the laboratory has shown that HIV-1 Tat can increase the 
activity of the AICDA R1 promoter in a dose-dependent manner 144. To verify these 
experiments luciferase reporter assays were repeated. A significant increase of 1.6-fold was 
observed in promoter activity in the presence of HIV-1 Tat, compared to the control (Figure 
3.1) hence confirming the previous results. 
 
 
Figure 3.1: HIV-1 Tat enhances the activity of the AICDA R1 promoter. HT1080 cells were 
transfected with 500ng of the AICDA WT promoter (pGL3-AICDA-R1) along with 400ng of 
the HIV-1 Tat expression vector (pcDNA-Tat) or 400ng of the Empty pcDNA3.1 as control. 
Fold activation was obtained by comparing the relative luciferase units (RLU) of the HIV-1 Tat 
transfected groups to their empty transfected controls. Statistical analysis was done using 
GraphPad PRISM 7 with a two-tailed Student’s t-test. Significance *(p<0.05). The graph is 
representative of at least three separate repeats. 
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3.3.2 PROMO analysis identifies multiple putative TFBS within the AICDA R1 
promoter 
 
Using the online software PROMO, a comprehensive analysis of the AICDA R1 promoter was 
done to identify putative TFBS. Sites were mapped onto the promoter sequence of AICDA and 
the result is displayed in Figure 3.2. This analysis was done to identify TFBS which may 
potentially mediate the response observed in the result shown in Figure 3.1. To begin to 
address this, sequential deletion constructs of the R1 AICDA promoter was made. These 













Figure 3.2: Transcription factor binding sites located on the AICDA R1 promoter as identified by PROMO. The 2141 bp FL AICDA 
promoter construct (pGL3- AICDA-WT) was analysed for TFBS using PROMO.  Sites are represented as different coloured shapes which are 
labelled in the key and the transcription start site (TSS) is denoted by a black arrow. Sequential deletion constructs were designed to remove 
specific TFBS. Shortened promoter constructs are labelled accordingly on the right side of the diagram (pGL3-AICDA-DF1, pGL3- AICDA -DF2 
and pGL3- AICDA -DF3 and pGL3-AICDA-DF4 ).  
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3.3.3 Sequential deletions of the AICDA R1 promoter do not lead to a decrease in 
activity in the presence of HIV-1 Tat  
 
To identify the minimum promoter region which could be mediating this enhanced expression, 
a similar strategy was adopted as the one described for the c-MYC promoter in Chapter 2 in the 
creation of deletions construct for the AICDA promoter. This was followed by luciferase assays 
to assess whether the loss of specific promoter regions affected the observed activation. The 
use of sequential deletions constructs of the AICDA promoter in luciferase assays did not show 
a significant decrease in the promoter activity in the presence of HIV-1 Tat (Figure 3.3). While 
no loss in promoter activation was observed when the regions from -1729 bp to -534 bp (DF1 
– 3) were deleted, intriguingly activation was enhanced when a region spanning -534 bp to -







Figure 3.3: Sequential deletion of the AICDA R1 WT promoter does not abrogate the 
increased promoter activation under the influence of HIV-1 Tat. HT1080 cells were 
transfected with 500 ng of the AICDA R1 WT promoter (pGL3-AICDA-WT) or deletion 
constructs (pGL3-AICDA-DF1, pGL3-AICDA-DF2, pGL3-AICDA-DF3 and pGL3-AICDA-
DF4) along with 400 ng of the HIV-1 Tat expression vector (pcDNA-Tat) or 400 ng of the 
Empty pcDNA3.1 as control. Fold activation was obtained by comparing the relative luciferase 
units (RLU) of the HIV- 1Tat transfected groups to their empty transfected controls which were 
set to 1. One-way ANOVA tests were done using GraphPad PRISM 7. Significance *(p<0.05), 
**(p<0.005) and ****(p<0,0001). The graph is representative of at least three separate repeats. 
 
3.3.4 HIV- 1 Tat elicits a dose-dependent increase in the activity of the R2 and R4 
regulatory regions.  
 
As discussed in Chapter 1, four regulatory regions have been described for the AICDA gene 
(see Figure 1.3) of which R1, R2 and R4 have defined roles in activating/repressing AICDA 
expression. To further assess the ability of HIV-1 Tat to affect AICDA transcription, luciferase 
assays were carried out using pGL3 constructs containing the R2 and R4 regulatory regions 
cloned upstream of the luciferase gene. Interestingly, both regions showed a dose-dependent 





Figure 3.4: HIV-1 Tat induces activation of both the AID R2 and R4 regulatory regions. 
A)  HT1080 cells were transfected with 500 ng of the AICDA R2 promoter (pGL3-AICDA-
R2) along with 200-400 ng of the HIV-1 Tat expression vector (pcDNA-Tat) or 200-400 ng of 
the Empty pcDNA3.1 as control. B) HT1080 cells were transfected with 250 ng of the AICDA 
R4 promoter (pGL3-AICDA-R4) along with 100-200 ng of the HIV-1 Tat expression vector 
(pcDNA-Tat) or 100-200 ng of the Empty pcDNA3.1 as control. Fold activation was obtained 
by comparing the relative luciferase units (RLU) of the HIV-1 Tat transfected groups to their 
empty transfected controls which were set to 1. Statistical analysis was done using one-way 
ANOVA with GraphPad PRISM 7. Significance *(p<0.05), **(p<0.005) and ***(p<0,0005). 
The graphs are representative of at least three separate repeats. 
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3.3.5 AID and yH2AX protein levels are elevated in HIV-1 Tat expressing BL cells  
 
To determine if the increased AICDA expression previously shown was conserved at the protein 
level, electroporation of Ramos cells with an HIV-1 Tat expression construct was performed 
followed by western blot analysis. As shown in Figure 3.5A, an increase in AID protein levels 
was observed in cells expressing HIV-1 Tat compared to empty control. We and others have 
previously reported that an increase in AID is accompanied by upregulation of the double-
strand DNA break marker, phosphorylated H2AX (γH2AX) 120,163. Indeed, we found a 








Figure 3.5: HIV-1 Tat expression in Ramos cells leads to increased AID and γH2AX 
protein levels. Cells were electroporated with 15 µg of the HIV-1 Tat expression vector 
(pcDNA-Tat) or 15 µg of the pcDNA3.1 plasmid as a control. A) AID western blot. B) γH2AX 
western blot. Bar graphs represent densitometric analysis (ImageJ).  Fold increase was obtained 
by comparing the relative densitometric units of the HIV-1 Tat electroporated cells to the 
negative control cells, which were set to 1, after normalising to loading control (p38).  
 
3.3.6 Expression of HIV-1 Tat in BL cells leads to a decrease in hsa-miRNA-181b-5p 
levels. 
 
Our assays on the R1 promoter indicate that the observed increase in AID expression in the 
presence of HIV-1 Tat is unlikely to be via a direct mechanism involving this region but could 
potentially be regulated indirectly at the post-transcriptional level. AID has been reported to be 
the target of a handful of microRNAs.  Furthermore, and as stated earlier, a study on HIV-
associated neurocognitive disorders found that HIV-1 Tat could inhibit hsa-miRNA-181b in 
astrocytes 141. This miRNA has been shown to directly bind to and repress the murine Aicda 
3’UTR 142. Analysis of the human AICDA 3’UTR revealed that it contains three predicted hsa-
miRNA-181b-5p binding sites with two of the sites sharing significant homology between the 


















Figure 3.6: hsa-miR-181b-5p predicted binding sites within the 3’UTR of the AICDA 
mRNA. A) Putative sites for hsa-miR-181b-5p on the human AICDA 3’UTR were obtained 
using miRTarBase 164 and confirmed through searches on alternative bioinformatics tools: 
miRmap 165 and TargetScan 166. B) The human and mouse AICDA 3’UTR was aligned using 
the online sequence alignment tool MultAlin167. Blue nucleotides indicate sequence 
differences, red nucleotides show sequence conservation and black nucleotides indicate 
sequences only present in one of the 3’UTRs. The three putative binding sites for hsa-miRNA-





















To determine if HIV-1 Tat can alter the expression of hsa-miR-181b-5p in B cells, Ramos cells 
were electroporated with pcDNA-Tat or pcDNA3.1 empty control and RNA was isolated to 
quantify the levels of hsa-miRNA-181b-5b. Here it was found that hsa-miRNA-181b-5p is 
significantly downregulated when HIV-1 Tat is expressed 24hrs after electroporation, 




Figure 3.7: hsa-miRNA-181b-5p is downregulated in HIV-1 Tat expression BL cells. 
Ramos cells were electroporated with pcDNA-Tat or pcDNA3.1 control. miScript qRT-PCR 
results are expressed as fold change relative to pcDNA3.1 negative control which was set to 1. 
U6 primers were used as an internal control. Statistical analysis was done using GraphPad 
PRISM 7 with a two-tailed Student’s t-test with a two-sided t-test, **(p<0.005).  The graph is 








3.3.7 An hsa-miRNA-181b-5p mimic interacts with the AICDA 3’UTR, leading to 
translational repression.  
 
To further investigate and confirm the HIV-1 Tat – miRNA181b – AID axis, HT1080 cells 
were transfected with the pGL3-AICDA-3’UTR construct along with 50 nM of a commercially 
available hsa-miRNA-181b-5p mimic or 50 nM of the Allstar siRNA negative control (Figure 
3.8). Significant repression of luciferase activity was observed in the hsa-miRNA-181b-5p 
mimic transfected cells compared to no RNA control and siRNA negative controls.   
 
Figure 3.8: The hsa-miRNA-181b-5p mimic represses the AICDA 3’UTR. Luciferase 
reporter assay investigating the effect of hsa-miRNA-181b-5p on the AICDA full-length 
3’UTR.   HT1080 cells were transfected with 350 ng of the pGL3-AICDA 3’UTR, along with 
50 nM of the hsa-miRNA-181b-5p mimic or Allstar siRNA negative control. Fold activation 
was obtained by comparing the relative luciferase units (RLU) of the hsa-miRNA-181b-5p or 
siRNA control transfected groups to the no RNA empty transfected controls, which were set to 





The sequential deletion of the AICDA R1 promoter was unable to reduce the HIV-1 Tat-
mediated promoter activation. This indicates that the increase in AICDA transcription via the 
R1 promoter is unlikely to occur as a direct effect of HIV-1 Tat on the promoter. A possible 
mechanism could be that HIV-1 Tat induces changes to cellular pathways which in turn activate 
the R1 promoter. Further interrogation is needed to decipher this,  for instance, potential 
cellular pathways which are activated by HIV-1 Tat could be identified through the use of 
inhibitory molecules that target specific pathways, and assess if these inhibitory interventions 
abrogate the observed HIV-1 Tat-mediated R1 promoter activity. It is also possible that HIV-
1 Tat may be mediating the activation via sites present within the minimal promoter region of 
116 bp present in pGL3-AICDA-DF4. Of Note, the 116 bp region contains multiple C/EBP 
binding sites which could be abolished through SDM to determine if they are involved in this 
mechanism. A future avenue would be to perform ChIP assays with HIV-1 Tat specific 
antibody to determine whether HIV-1 Tat potentially interacts with the R1 promoter. If no 
region is enriched it would mean that there is less likelihood that HIV-1 Tat is directly 
interacting with this regulatory region and that the observed increase in promoter activity is not 
specific.  Interestingly, the observed increase in promoter activity in the presence of HIV-1 Tat 
was further enhanced when only a small region of 116 bp upstream of the TSS was present. 
The region of the promoter lost within this deletion construct could harbour repressive 
elements, proximal to the core promoter, which keeps the AICDA R1 promoter in check. 
Therefore, the loss of these elements might be amplifying the observed HIV-1 Tat activation. 




The effect of HIV-1 Tat on the AICDA regulatory regions R2 and R4 was also assessed and 
both regions were found to be significantly enhanced by HIV-1 Tat, more robustly than the R1 
promoter. These regions contain multiple TFBS that regulate AICDA expression including 
STAT6, C/EBP and SMAD3/4 in R4 and MYB, PAX5, E2A and E2F in R2. Due to time 
constraints, further interrogation of this result could not be carried out, however, this does form 
part of future studies in the laboratory to continue to uncover the complete picture of HIV-1 
Tat’s role in the regulation of AID. It would be worthwhile to investigate whether HIV-1 Tat 
binds to and/or interacts with these TFs and TFBS given that HIV-1 Tat has previously been 
reported to interact with some of these proteins 168. 
 
AID’s physiological function is to induce changes in DNA which result in the activation of 
DNA repair response. Depending on the mechanistic responses that occur after deamination, 
there can be the formation of DSBs. An important marker for DNA DSB is the phosphorylation 
of Serine 139 on histone H2AX, producing γH2AX 169,170. This modification to the H2AX 
histone can be used to evaluate the level of DNA damage occurring in the cell after specific 
stimuli171. This study shows that BL cells expressing HIV-1 Tat, not only have increased AID 
protein expression but also elevated phosphorylation of H2AX. This finding is in line with 
what has been reported recently by our group where HIV-1 Nef induced AID expression 
correlated resulted in increased genomic instability 120. Taken together, this study, as well as 
other recent publications, give evidence of deleterious HIV-1 Tat modulation of AID activity 
within BL cells both at the transcriptional and posttranscriptional levels.  
 
Our result of the R1 promoter suggested that the observed increase in AID expression could be 
due to interaction with other regulatory regions or potentially through events happening at the 
post-transcriptional level. AID is tightly regulated within B cells. These mechanisms of 
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regulation prevent off-target AID activity which could be oncogenic due to its ability to mutate 
DNA. One of the ways a cell regulates the expression of genes is through RNA interference 
172. miRNAs are short non-coding RNAs that target specific, often conserved, 3’UTR regions 
of mRNA targeting them for repression/degradation 173,174. In the context of AICDA, a handful 
of miRNAs have been implicated in its repression. Of importance to this study is hsa-miRNA-
181b-5p which has been implicated in the murine Aicda repression and has also been reported 
to be downregulated in astrocytes by HIV-1 Tat in the context of HIV associated 
neurocognitive disorder (HAND). In our study, we show that the presence of HIV-1 Tat led to 
a significant decrease in hsa-miRNA-181b-5p in BL cells. It is important to note that this 
decrease was consistently observed despite the relatively low transfection efficiency of Ramos 
cells. Within the context of HIV infection, this has an important implication for AICDA 
regulation, as it suggests that if hsa-miRNA-181b-5p is repressed by HIV-1 Tat, AICDA/AID 
levels would increase due to the loss of miRNA interference with mRNA translational 
processes, and this is indeed the case as shown in this study. The precise mechanism whereby 
HIV-1 Tat alters miRNA expression remains unclear. A potential mechanism behind this was  
proposed by the Jeang group, where HIV-1 Tat binds to Dicer protein thereby interfering with 
miRNA processing 175,176. Future work needs to be done with a broader approach to investigate 
the extent of HIV-1 Tat and BL miRNA associations and the consequential changes in the 
miRNA targetome. A potential way to tackle this, which is currently being developed by our 
research group, would be to employ AGO2-RIP-ChIP  followed by microarray or RNA-Seq 
analyses to identify actively targeted mRNA sequences as a result of this HIV-1 Tat-mediated 
miRNA deregulation 177. 
 
The study that first implicated hsa-miRNA-181b-5p in the repression of AID was done using 
the mouse Aicda 3’UTR.  Although the human and mouse AICDA 3’UTR share conserved 
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regions, it has not been shown if hsa-miRNA-181b-5p directly interacts with the human AICDA 
3’UTR. The full-length sequence was cloned into the pGL3-Promoter vector and this construct 
was used in luciferase assays to assess the ability of hsa-miRNA-181b-5p to repress the full-
length 3’UTR. Our result aligns with what was reported by Yébenes et al (2008) although their 
finding was in the context of the murine Aicda 3`UTR. Future work should focus on confirming 
that the putative hsa-miRNA-181b-5p binding sites within the 3’UTR do indeed mediate this 
repression. To this end, SDM can be employed to sequentially disrupt the three hsa-miRNA-














































The last two decades have seen important advances in our understanding of HIV-1 biology, the 
progression of AIDS and the comorbidities associated with this life-long viral infection.  
Amongst the common comorbidities are the AIDS-defining cancers which include BL and 
DLBCL. These cancers are often reported to be aggressive in HIV infected patients, even those 
whose HIV viral load has been suppressed, with these patients experiencing poorer than 
average outcomes. In recent years the new concept of HIV having direct oncogenic effects in 
patients has emerged, supported by molecular studies showing the ability of components of the 
virus to induce cancer-driving changes in cellular pathways. The studies carried out and 
presented in this thesis contributes to this body of work, and serve to enhance our understanding 
of these phenomena 110,116,120,144,178.  
 
This work presents a novel mechanism of how HIV-1 Tat interacts with the promoter region 
of c-MYC to induce its transcription, and how it enhances AID expression through two 
independent mechanisms; by inducing the activation of three regulatory regions of the  AICDA 
gene and through the repression of hsa-miRNA-181b-5p-mediated translational interference. 
In Figure 4.1 we summarise some of the pathways and mechanisms whereby HIV-1 proteins 
promote oncogenesis in B cells and demonstrate how the findings of this present study 
complement the growing body of evidence for the direct role of HIV-1 in B-cell lymphoma 
development. 
 
Not only could HIV be driving oncogenic pathways in patients harbouring high viral loads, but 
also in those who are virally suppressed through effective antiretroviral therapy. Importantly, 
some studies suggest that latently infected memory CD4 T cells are not the only compartments 
of HIV persistence, but that myeloid cells, and possibly haematopoietic progenitors, can also 
serve as long-term viral reservoirs 179. Furthermore, circulating HIV-1 proteins remain 
87 
 
detectable in the sera of HIV positive individuals including those that are receiving HAART 
and are virally-suppressed110,180,181. These proteins have been shown to be able to either 
translocate through the cell membrane or interact with cell surface receptors, culminating in 
the deregulation of cellular pathways, altering host gene expression, and disrupting genomic 
stability 112,137.   
 
Previous work in our groups which formed part of a Master’s thesis showed that BL cells 
incubated with recombinant HIV-1 Tat protein had elevated c-MYC mRNA and protein, and is 
in support of the published work by Germini et al (2017) demonstrating HIV-1 Tat’s ability to 
promote the colocalization of the c-MYC and IGH loci in B cells from HIV positive patients. 
They further demonstrated that along with this increased co-localization there was also 
evidence of DNA DSBs in these loci 139,144. Additionally, our research group and others have 
uncovered oncogenic properties associated with the HIV-1 protein Nef.  Mdletshe et al (2020) 
found that BL cells exposed to HIV-1 Nef recombinant protein have significantly elevated 
levels of c-MYC mRNA and protein expression, with a concomitant increase in genomic 
instability120. Furthermore, Li et al (2010) demonstrated that HIV-1 p17 promotes c-MYC and 
CREB phosphorylation in B cells through the activation of the cAMP/PKA and MEK/ERK 
signalling pathways, thereby enhancing the DNA binding activity of these TFs 116. The binding 
of p17 to the receptors CXCR1 and CXCR2 induces the activation of these signalling pathways, 
as well as the AKT/PI3K pathway, and has also been reported to enhance angiogenesis, a 
feature of more advanced stage disease 182–184. Taken together these studies show that, as a 
result of HIV-1 infection, the expression and function of c-MYC is enhanced in B lymphocytes 




 The direct perturbation of AID expression by pathogenic agents like EBV, Helicobacter 
pylori, Plasmodium falciparum and HIV-1 has been a focal point of research within the field 
of diseases caused by infectious agents185–188. In the context of HIV-1 infection, Sall et al 
(2019) demonstrated that within B cells of both healthy donors and HIV positive patients, 
recombinant HIV-1 Tat protein induces increased AICDA mRNA expression and H3 
acetylation at the R1 promoter region, indicative of active chromatin. Concomitant with this, 
they observed γH2AX foci formation at the IGH locus through immuno-3D FISH. Our data 
also corroborates the Sall et al (2019) findings by showing that BL cells transiently transfected 
with HIV-1 Tat have increased AID protein expression and show increased DNA damage 
demonstrated by heightened γH2AX levels. AID targeting to DNA is complex and not fully 
understood. However, a proposed requirement for its targeting to DNA is active transcription, 
with AID activity often mapped to actively transcribed regions 91,92,189. This phenomenon could 
be a result of ssDNA exposure within R-loops during transcription or due to AID’s association 
with the transcriptional machinery, giving it access to DNA 190–193. However, this is not enough 
to explain the selectivity of AID towards certain actively transcribed genes over others, 
suggesting the importance of other secondary DNA structures necessary for AID’s enzymatic 
activity. For example, G-quadruplexes have been shown to be preferentially targeted by AID 
194.  Notably, known targets of AID like c-MYC, BCL2 and IGH  contain such structures within 
their promoter regions (c-MYC and BCL2) and S region (IGH) 195–197. Taken together, this 
could explain why HIV positive individuals have an increased risk of developing BL compared 
to the general population, despite the advent of HAART. Specifically, in B cells of HIV 
positive individuals, c-MYC translocations could be favoured due to i) HIV-1 Tat/Nef/p17-
mediated increased c-MYC transcription and activity, ii) the increased c-MYC and IGH loci co-
localization induced by HIV-1 Tat and iii) the concomitant elevation in AID protein levels and 
off-target activity promoted by HIV-1 Tat and Nef. Altogether, we propose that these features 
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potentiate a highly favourable environment for translocation and other mutational events to 
occur, thereby enhancing cell proliferation and other cellular phenotypes which support BL 
progression.  
 
Ultimately, our increased understanding of the oncogenic features of HIV-1 will lead to novel 
avenues for therapy, disease monitoring and prevention. Potential therapies could be aimed at 
blocking the interactions between specific HIV-1 proteins and their host co-factors. For 
instance, the use of small-molecule inhibitors could be used to prevent p17’s binding to the 
CXCR1/2 receptors on the B cell surface, therefore blocking the signalling pathways 
downstream of this interaction. Concurrently, other methods could be implemented to block 
HIV-1 Tat from inducing transcriptional activation of host genes. This could be achieved 
through the use of  HIV-1 Tat inhibitors like Didehydro-Cortistatin A which blocks HIV-1 Tat 
function 198,199. Furthermore, the monitoring of the levels of circulating viral proteins in the 
sera of HIV positive patients could be used as a factor to assess the risk of developing disease. 




HIV-BL is an aggressive disease with an often poor prognosis in the South African setting. 
Finding novel ways to tackle this malignancy is imperative to the improvement of treatment 
and outcome. This thesis describes three novel mechanisms which implicate HIV-1 Tat in the 
pathobiology of HIV-BL. (1) We show that HIV-1 Tat, through interacting with JunB, binds 
to the c-MYC promoter resulting in the increased transcription and protein levels in BL cells, 
(2) HIV-1 Tat activates the AICDA R1, R2 and R4 regulatory regions, upregulating 
transcription, and (3) HIV-1 Tat represses hsa-miRNA181b-5p, alleviating AICDA 3’UTR 
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repression further increasing AID protein levels in BL cells. Together, these findings not only 
highlight the complexity of HIV-1 Tat activity within BL cells but also the importance of 






Figure 4.1: Schematic diagram showing the different cellular mechanisms whereby HIV-
1 viral proteins have been shown to promote B-cell lymphomagenesis. Infected CD4+ cells 
actively secrete viral proteins (including HIV-1 Tat, Nef and p17) into circulation. Circulating 
HIV-1 Tat and Nef proteins in the sera of HIV positive people can translocate into B cells 
112,137. Upon entering the nucleus HIV-1 Tat associates with host factors like JunB and binds 
to the c-MYC promoter (Chapter 2). HIV-1 Nef also induces c-MYC promoter activity resulting 
in increased transcription via a yet unidentified mechanism 120. HIV-1 Tat can enhance the 
transcription of the AICDA gene via three of its regulatory regions (Chapter 3).  Additionally, 
HIV-1 Tat inhibits the AICDA repressor hsa-miRNA-181b-5p, further increasing AID protein 
levels (Chapter 3). The HIV-1 Nef protein induces AID transcription via an as yet undescribed 
mechanism 120. Increased AID protein in B cells promotes the occurrence of off-target DSBs 
and mutagenesis culminating in c-MYC/IGH translocations and other pro-cell 
survival/proliferative advantages 52,88,90. Increased c-MYC transcription and/or translocations 
result in the overexpression of the c-MYC protein, coupled to HIV-1 p17 induced c-MYC 
protein phosphorylation via the cAMP/PKA and MEK/ERK signalling pathways, promotes c-
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Lysogeny Broth (LB) (1 L) 
Dissolve 10 g of LB powder media in 800 mL ddH2O and adjust the volume to 1 L 
Sterilise by autoclaving and store at room temperature 
 
LB agar 
Mix 1.5 g Agar and 2 g LB powder media in 100 mL ddH2O 
Sterilize by autoclaving and store at room temperature 
 
100 mM CaCl2 (50 mL) 
Dissolve 0.735g CaCl2 in 40 mL ddH2O 
Adjust volume to 50 mL with ddH2O and filter sterilise using a 0.2 µm syringe filter 
Make fresh before use each time and store at 4°C 
 
25% glycerol stocks 
Add 0.5 mL 50% sterile glycerol to 0.5 mL bacterial liquid culture and mix gently 










Supplemented growth media for Ramos cell line 
Add 5 mL (10%) of FBS and 0.5 mL of P/S to a 50 mL sterile conical tube 
Fill up to 50 mL with RPMI-1640 media and mix 
Store at 4°C until needed 
 
Serum rich media for post-electroporation incubation 
Add 10 mL (20%) of FBS and 0.5 mL of P/S to a 50 mL sterile conical tube 
Fill up to 50 mL with RPMI-1640 media and mix 
Store at 4°C until needed 
 
Supplemented growth media for HT1080 cell line 
Add 5 mL (10%) of FBS and 0.5 mL of P/S to a 50 mL sterile conical tube 
Fill up to 50 mL with DMEM media and mix 
Store at 4°C until needed 
 
Freezing media for Ramos and HT1080 cell lines 
10% DMSO and 10% FBS in RPMI-1640/DMEM media (as indicated above for each cell 
line) 







0.1% diethyl pyrocarbonate- (DEPC) treated water 
Fill a 5 L beaker with autoclaved water and add 1 mL of DEPC per 500 mL of ddH2O 
Add a magnetic stirrer bar and place on the stirrer for a few hours (3-5 hrs) 
Place the beaker in the fume hood overnight, remove the stirrer bar and autoclave to 
inactivate the remaining DEPC 
Store the H2O at room temperature until needed 
 
0.1% diethyl pyrocarbonate- (DEPC) to treat plasticware 
Fill 5 L beaker with ddH2O and add 1 mL of DEPC per 1 L of H2O 
Add stirrer bar and plasticware (pipette tips, centrifuge tubes) 
Place on the magnetic stirrer for 3-5 hrs 
Place the beaker in a fume hood overnight 




10x Tris/Borate/EDTA (TBE) buffer (1 L) 
Dissolve 108 g Tris and 55 g Boric acid in 900 mL ddH2O using a magnetic stirrer 
Add 40 mL EDTA (0.5M pH 8) 
Adjust to 1 L 
Store at room temperature 
 
1x TBE (1 L) 
Measure 100 mL of 10x TBE stock 
Fill up to 1 L using ddH2O 
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2x RNA loading buffer (1 mL) 
Add 900 μL formamide, 99 μL sucrose, 0.5 μL Bromophenol Blue and 0.5 μL Xylene Cyanol 
Store at room temperature 
 
10x DNA loading dye (20 mL) 
Mix 0.025 g of Xylene cyanol, 0.025 g of Bromophenol Blue to 6.25 mL of ddH2O and 
dissolve using a magnetic stirrer  
Add 1.25 mL of 10% SDS and 12.5 mL of glycerol 
Aliquot and store at room temperature 
 
1%/1.5% agarose gel (100 mL) 
Weigh 1 g/1.5 g agarose and add to 100 mL 1x TBE 
Dissolve all the agarose by heating using a microwave 
Allow to cool and then add 5 μL Ethidium Bromide (EtBr, 0.5 mg/mL) 




RIPA Buffer (50 mL) 
Mix 1.5 mL 150 nM NaCl; 0.5 mL 1% Triton X100; 0.5 mL 0.1% SDS; 0.5 mL 10 mM Tris 
pH 7.5; 0.5 g 1% deoxycholate powder 






7x protease inhibitor 
Add 1 protease inhibitor tablet to 1.5 mL 1x PBS and allow to dissolve 
Aliquot and store at -20°C 
 
RIPA solution (1 mL) 
Combine 858 μL RIPA buffer with 142 μL 7x protease inhibitor 
Make fresh before each use and store at 4°C 
 
2x Laemmli buffer (10 mL) 
Mix 0.125 mM Tris-HCL pH 6.8, 4% SDS, 10% β-mercaptoethanol, 20% glycerol, and 
0.005% of bromophenol blue in a final volume of 10 mL made up with ddH2O, aliquot to 
1.5mL Eppendorf tubes and store at -20°C 
 
SDS-PAGE Reagents  
 
1.5M Tris pH 6.8 (500 mL) 
Dissolve 60.5 g Tris base in 300 mL deionized H2O 
Adjust pH to 6.8 with concentrated HCl and volume to 500 mL with ddH2O 
Store at 4°C 
 
1.5M Tris pH 8.8 (500 mL) 
Dissolve 60.5 g Tris base in 300 mL ddH2O 
Adjust pH to 8.8 with concentrated HCl and volume to 500 mL with ddH2O 




10% Sodium dodecyl sulphate (SDS) (100 mL) 
Dissolve 10 g sodium dodecyl sulphate crystals in 90 mL ddH2O 
Adjust volume to 100 mL with ddH2O 
Store at room temperature 
 
10% Ammonium persulfate (APS) (1 mL) 
Dissolve 0.1 g ammonium persulfate in 1 mL ddH2O 
Store at 4°C 
 
30% acryl-bisacrylamide mix (100 mL) 
Dissolve 29 g acrylamide and 1 g N.N’-methylenebisacrylamde in 60 mL ddH2O 
Heat the solution to 37°C to dissolve the chemicals 
Adjust volume to 100 mL with ddH2O 
Filter through 0.45 μM membrane 
Store at 4°C protected from light 
 
10x SDS-PAGE running buffer (1 L) 
Dissolve 10 g SDS; 30.3 g Tris and 144.1 g glycine in 800 mL ddH2O 
Adjust volume to 1 L with ddH2O 
Store at room temperature 
1x SDS-PAGE running buffer (1 L) 
Add 100 mL 10X SDS-PAGE running buffer to 900 mL ddH2O 





10x SDS-PAGE transfer buffer (1 L) 
Dissolve 144 g glycine and 38 g Tris in 800 mL ddH2O 
Adjust volume to 1 L with ddH2O 
Store at room temperature 
 
1x SDS-PAGE transfer buffer (1 L) 
Mix 100 mL 10X transfer buffer; 700 mL ddH2O and 200 mL isopropanol 
Make fresh on the day of running gel and store at 4°C 
 
1x Ponceau S staining solution (0.1% (w/v) Ponceau S in 5% (v/v) acetic acid) (50 mL) 
Dissolve 0.1g Ponceau S in 5 mL acetic acid 
Adjust volume to 100 mL with deionized ddH2O and protect from light 
Store at room temperature 
  
12% resolving gel for SDS-PAGE (7,5 mL) 
Mix 2.4 mL ddH2O; 3 mL 30% acryl-bisacrylamide mix; 1.95 mL 1.5M Tris (pH 8.8); 0.075 
mL 10% SDS; 0.075 mL 10% APS and 0.003 mL tetramethylethylenediamine (TEMED) 
(inside a fume hood) 
Pour into 1 mm glass plate, minimise exposure to air 
Add 1% SDS to set the top of the gel 
 
15% resolving gel for SDS-PAGE (7,5 mL) 
Mix 1.65 mL ddH2O; 3.75 mL 30% acryl-bisacrylamide mix; 1.95 mL 1.5M Tris (pH 8.8); 
0.075 mL 10% SDS; 0.075 mL 10% APS and 0.003 mL tetramethylethylenediamine 
(TEMED) (inside a fume hood) 
123 
 
Pour into 1 mm glass plate, minimise exposure to air 
Add 1% SDS to set the top of the gel  
 
3% stacking gel for denaturing SDS-PAGE (3 mL) 
Mix 2.1 mL ddH2O; 0.5 mL 30% acryl-bisacrylamide mix; 0.38 mL 1.5M Tris (pH 6.8); 0.03 
mL 10% SDS; 0.03 mL 10% APS and 0.003 mL tetramethylethylenediamine (TEMED) 
(inside a fume hood) 
Pour into 1 mm glass plate which has the set resolving gel, add comb and leave to set 
 
5x SDS loading dye (10 mL) 
Dissolve 1 g SDS (10%) and 0.004 g Bromophenol Blue (0.04%) in 5.25 mL ddH2O and add 
1.25 mL 2 M Tris-HCl pH 6.8; 3 mL 100% glycerol and 0.5 mL β-mercaptoethanol  




10xPBS (1 L) 
Weigh out 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4 and 2.4 g KH2PO4 and transfer to a 1 L 
beaker 
Dissolve in 800 mL ddH2O using a magnetic stirrer 
Adjust pH to 7.4 with HCl and volume to 1 L with ddH2O. 
Aliquot the 10x PBS and sterilize by autoclaving  





1x PBS (1 L) 
Measure 100 mL of 10x PBS and add to 900 mL ddH2O. 
Aliquot as needed and store at 4°C 
 
1x PBS/0.1% Tween (PBST) (1 L) 
Add 1 mL Tween-20 to 1x PBS made up to 1 L 
Mix well with magnetic stirrer bar 
Store at 4°C  
 
Blocking Solution (50 mL) 
Add 2.5 g non-fat powder milk (5%) and dissolve in 50 mL in PBST 
Store at 4°C 
 
1M Tris-HCl (pH 6.7) used in stripping buffer (200 mL) 
Dissolve 24.22 g Tris base in 160 mL ddH2O 
Adjust pH to 6.7 with concentrated HCl and adjust the volume to 200 mL with ddH2O 
Store at 4°C 
 
Stripping buffer (100 mL) 
Combine 0.69 mL 100 mM β-mercaptoethanol, 10 mL 2% SDS, 6.25 mL 62.5 mM Tris HCl 
(pH 6.7) adjusted with ddH2O to 100 mL 





ChIP buffers and reagents 
 
1% Formaldehyde  
Add 0.548 mL of 36.5% Formaldehyde stock solution to 20 mL of media containing cells 
 
1.25 M Glycine (100 mL) 
Dissolve 9.384 g Glycine in 100 mL 1x PBS 
Sterilise by autoclaving 
Store at room temperature 
 
NCP buffer I (50 mL) 
Mix a final concentration of 10mM EDTA, 0.5 mM EGTA, 10 mM HEPES pH 6.5 and 
0.25% Triton-X in a total of 50 mL ddH2O 
Store at 4°C  
 
NCP buffer II (50 mL) 
Mix a final concentration of 1mM EDTA, 0.5 mM EGTA, 10 mM HEPES pH 6.5 and 
200mM NaCl in a total of 50 mL ddH2O 




ChIP lysis buffer (10 mL) 
Mix a final concentration of 10 mM EDTA, 50 mM Tris pH 8.0, 1% SDS and 0.5% Triton-X 
in a total of 10 mL ddH2O 
Store at 4°C 
 
ChIP lysis buffer + protease inhibitors (2.5 mL) 
Add 0.0125 mL of 100 mM PMSF and 0.357 mL of 7x protease inhibitors to 2.13 mL of 
ChIP lysis buffer 
Make fresh each time before using and store at 4°C 
 
RIPA-IP buffer (20 mL) 
Mix a final concentration of 2 mM EDTA, 150 mM NaCl, 20 mM Tris pH 8.0 and 1% 
Triton-X in a total of 20 mL ddH2O 
Store at 4°C 
 
RIPA-IP buffer with protease inhibitors (1 mL) 
Add 0.005 mL 100 mM PMSF and 0.143 mL 7x protease inhibitor to a total of 1 mL RIPA-
IP buffer 





Wash buffer 1 (10 mL) 
Mix a final concentration of 2 mM EDTA, 150 mM NaCl, 20 mM Tris pH 8.0, 0.1% SDS 
and 1% Triton-X in a total of 10 mL ddH2O 
Store at room temperature 
 
Wash buffer 2 (10 mL) 
Mix a final concentration of 2 mM EDTA, 500 mM NaCl, 20 mM Tris pH 8.0, 0.1% SDS 
and 1% Triton-X in a total of 10 mL ddH2O 
Store at room temperature 
 
Wash buffer 3 (10 mL) 
Mix a final concentration of 1 mM EDTA, 250 mM LiCl, 10 mM Tris pH 8.0, 0.1% sodium 
deoxycholate and 1% Triton-X in a total of 10 mL ddH2O 
Store at room temperature 
 
Wash buffer 4 (10 mL) 
Mix a final concentration of 1 mM EDTA and 10 mM Tris pH 8.0 in a total of 10 mL ddH2O 





Extraction buffer (10 mL) 
Mix a final concentration of 1 % SDS and 1 M NaHCO3 in a total of 10 mL ddH2O 
Store at room temperature 
 
 
 
 
 
 
